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INTRODUCTION 
 
 Ever since the dawn of civilization, man has been striving to unfold the mysteries 
of nature and to understand the structure and purpose of his being. The Tamils who are 
inhabitating the southern peninsula of this subcontinent undertook a systematic study of 
the nature and its elements from which they had developed a highly systematized 
medicine which is known as Siddha system. Siddha system of medicine is well founded 
under the basic principles of nature and its elements after a careful and thorough study of 
the human system. 
 
 It is accepted by one and all that the Siddha system had wonderful achievements 
to its credit. The word Siddha means “eversure”, “true”, ever ready and everlasting. 
Siddha is one who attains kayasiddhi. 
 
 In the Siddha system the creation itself is said to be originated from Siva which 
forms the first matter and energy. The matter is compared to Siva and the energy to 
Sakthi. Though matter and energy are compared separately to male and female, they are 
inseparable and always spoken as one, as each cannot function without the help of the 
other. 
 
 Siddha system as practiced by our ancients has been associated with religion and 
philosophy and thus evidently based on truth. This system of medicine recognizes the fact 
that the human organs are only the material and the bodily representation of invisible 
energies or activities that pervade and circulate the whole cosmic system. 
 
 In Siddha medicine, the physiological function in the human system is mediated 
by three humours (doshas) 1. Vatham 2. Pitham 3. Kapam which are made of the five 
elements (bhutas) 1. Mann 2. Neer 3. Thee 4. Vayu and 5. Akayam. 
 
 If these three doshas function in perfect state, normal health is maintained. Any 
change in this proportion will lead to disease. 
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 The condition neerizhivu due to vitiation of kapa humour and is followed by 
pitham and vatha derangement. Consequently the seven udal thathus also gets affected 
and the patient becomes terminally ill. 
 
 Siddha system is famous in handling all kinds of plant products, poisons, salts and 
metals. This truth is clearly quoted in Theraiyar’s verse as, 
 
  “தகதி தா ப
ப ெசான நாடா சிகிைச 
  ஓதய லிய மேணா சிகிைச” 
 
 In these herbs maintain a natural ability within the body even in times of 
disharmony and diseases. Our ancient siddhars who were considered about the above 
secret had preferred mainly herbs to chemicals, metals etc. for treating patients, in view 
of its harmless effect. Thus Siddha system emphasizes the use of herbs, roots, stem and 
leaves. If these are not effective gradual use of metals and minerals is suggested. 
 
 The following verse shows in detail about this concept. 
 
   “ேவபா" தைழபா" மிசின$கா% 
   ெம%ல ெம%ல ப
ப ெச&ர பாேர” 
 
 Since early times, herbs have been used for healing purposes and maintaining 
good health. In treating the disease Neerizhivu large number of herbs, mineral etc have 
been successfully tested in laboratory. The drug Kovai Kizhangu Choornam indicated for 
Neerizhivu in Siddha literatures. In this dissertation the author has to evaluate the 
Antidiabetic activity of Kovai Kizhangu Choornam. 
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AIM AND OBJECTIVE 
 
AIM: 
 
 The aim of the dissertation is to evaluate the efficacy of Kovai Kizhangu 
Choornam for Neerizhivu (Diabetes mellitus). 
 
OBJECTIVE: 
  
 Neerizhivu is a chronic metabolic disorder characterized by hyperglycaemia, 
glycosuria, pruritis vulva, balanitis, weight loss and nonspecific malaise. It is a disease 
causing serious and long term complications. There is no permanent remedy for 
neerizhivu in conventional medicine. The people are searching for an uncomplicated and 
managing therapy for neerizhivu. 
 
 Since, no analysis has been made so far in Kovai Kizhangu Choornam for the 
disease Neerizhivu. So, the author has selected the drug to prove its efficacy on the same. 
 
 The efficacy of Kovai Kizhangu Choornam has been evaluated in following 
aspects: 
 
• Collection of literary evidences in Siddha and botanical aspects. 
• Biochemical analysis 
• Pharmacological study 
• Clinical assessment 
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GUNAPADAM ASPECT 
ேகாைவ (Coccinia grandis) 
 
ேவ	 ெபயக: 
   “ேகாைவட ேபதைனேய றேக 
    ெகா	 கனயா ணலய நாமதி 
   மாைவ மன%ழகி மாதா' (ரதியா 
    மப க*'ப+ ேபாதனாசன யா' 
   யாைவ யன- வ-லியதா பழதி 
    யடகாத க'ப+ காசினாவ+ 
   .ைவ /தகதி யா' ெவைள .வ+ 
    ெபானாம ெம-லா ேகாைவ ேபேர”1 
        பா. எ3: 828 
 ெகா	கன, ணலயனாமதி, மன%ழகி, மாதா'(ரதி, 
க*'ப+, ேபாதநாசின, அைலவ-லி, யதாபழதி, க'ப+, காசினான, 
/தகதி, ெவைள.வ+. 1 
 அேசாகி, அ6ட7தா, அ3ண-வ-லி, அய-வ-லி, அைரய 
வ+ேராதி, ஆவார 9லி, ஆைவயண-, கமப+, மேகாைவ, 
கடகாமாகார', வ6:;	கன, ள< ெகா-லி, ேகாய+லக', சிராவ+, 
சிவனா பாக-, சீரான ப+'ப+, சீவக 9லி, /தகதி, ெசேகாைவ, ெச'ப+, 
தளவா>ேகாைவ, திர6:ேகாைவ, 3:, ந7., ந-லேகாைவ, ப+'பக', 
ப+'ப', ப+'ப+, ப+'ப+ைக, ெப?ேகாவ+க', மகாசராவ+, ம3@%ழகி, 
மப, மப7, ம7ேகாைவ, வ6டகா79லி, வ6டேகாைவ, வ+'பக', 
வ+'ப+, ெவைள.வ+, ேவ7ெகாAைவ. 43 
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 சிவனா பாைவெகா:, 3டBகா7, ெப?ேகாவ+காகெகா:, 
ரதேகாைவெகா:, வ+'பகெகா:. 10 
 ெகாAைவ, ெதா3ைட. 11 
 அரச. 12 
 
ேகாைவய+ வைகக: 
 ணபாட' 9லிைக வப+- Cைவய+ அ:பைடய+- இன( 
ேகாைவ, ைக( ேகாைவ என இர3 வைக', நிறதி அ:பைடய+- 
க?ேகாைவ எ	', ேகாைவய+ைலய+ உ?வைத', நிறைத' 
ெகா3 9வ+ரலிேகாைவ, ஐவ+ரலிேகாைவ, நாமேகாைவ எ	' 
9	 வ+தமாக றிப+டப6ளன. 
 இ<த ஆ>Gகாக ஆசி7ய எ' கிைடக:ய ைக(ேகாைவ 
கிழைகேய பயபதிளா. 
 
பயப' உ	(: 4 
 இைல, கா>, கிழ, த3, வHற- 
 
ைக( ேகாைவ: 
Cைவ  : ைக( 
தைம : ெவப' 
ப+7G  : கா( 
 
இன( ேகாைவ: 
Cைவ  : இன( 
தைம : த6ப' 
ப+7G  : இன( 
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ெச>ைக: 
 ெபா – ேகாைழயகHறி, இசிவகHறி, %ைறெவபகHறி 
 
இைல: 
 இதனா- க3 ளJசி உ3டா'. ெப?'(3, சி	 சிர, உட- 
ெவைக, நKரைட( நK'. இத ரசைத வ+யைவ உ3 ப3@வதH 
உடலி- .சலா'. 
 
கா>: 
 காயா- Cைவய+ைம, நKகா ெவப', கப', Cர' இைவ ேபா'. 
இளகாைய வாய+லி6 ெம	 ப நாகி (3க நK'. 
 
வHற-: 
 வHறலா- Cைவய+ைம' கரபா;' நK'. 
 
கிழ: 4 
  “%ேதாட' /ைலப+த' 96டL சிைவேநா> 
  எCவா சகப' இன(நK – இதைன 
  6ேடா டகH	 ளJசிேயா காரைத 
  கா6:யேகா ைவகிழ கா3” 
 இதனா- %ப+ண+, கீ-கள- உ3டா' த-, அழ- ேநா>, 
நK7ழிG, பைடக, நா(3, இைர(, ேகாைழ இைவக நK'. 
 கிழகி சாHைற ஓ உJசிகர3: %த- 9	 உJசிகர3: 
வைர ெகாக நK7ழிG, பைட நK'. 
 கிழகி சாHைற நK7ழிG ம?<க ைணயாக வழகலா'. 
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 இத த3 அ-ல கிழைக ெகாக, நKக6ைட உைட நKைர 
ெவளப'. 
 
ேகாைவ ேச?' ம?<க: 
1. அைப ேகாைவகிழ கஷாய' 
 தK?' ேநா>க : ேகாைழ, இரத ப+த', நK7ழிG 
 
2. கைலமா ெகா'( பHப': 3 
 கைலமா ெகா'ைபJ Cதி இைழ ேகாைவJ சாHறி- ஒ?நா 
ஊறைவ ம	நா நறாக காயைவ ஓ6:லி6J சீைலம3 ெச> 50 
வர6:ய+- (டமிட பHபமா'. 
 அ;பான'  : ேத, ெந>, ெவ3ெண> 
 தK?' ேநா>க : Uய', இ?ம-, ஈைள, உWண', நKரைட( 
 
3. தி7க மாதிைர: 3 
 ேகாைவ இைலJசாHறி- அைர (டமி6 எத சிலாச 8 பல', 
C /ரண' 1 பல', திப+லி ேபா: 1 பல' இவHைற ேகாைவ 
இைலJசா	 வ+6 அைர மாதிைரகளாகJ ெச>யG'. 
 அளG   : 1-2 மாதிைரக 
 அ;பான'  : ெவ<நK, பா- 
 தK?' ேநா>க : Cர', கபேராகக, அதிசார ச<நிபாத Cர' 
 
4. %J ெச<*ர': 3 
 Cதித % 1 பல' எ %-ைலJ சா	, ம?ெகா\<J சா	, 
ேகாைவJசா	 வ+6 அைர வ+-ைல த6: காய ைவ (டமி6 எக 
பHபமா'. 
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 அ;பான'  : நK, சகைர, ெந>, பைன ெவ-ல' 
 தK?' ேநா>க : Uய', /ைல, ேமக', சன 
 
5. பால சLசீவ+ எ3ெண>ீீீ : 
 அளG   : உJசிகர3:யளG காைல ம6' 
 தK?' ேநா>க : பதிெண3 கணக 
 
6. கண ைதல': 
 தK?' ேநா>க : கண', ெவ6ைட 
 
7. ஆடாேதாைட ெந>: 
 அளG   : காெசைட உ ெகா ேம_ 
வாைல ேபாட நா6ப6ட Cர' தK?'. 
 
8. சவாக ரசாயன': 
 அளG   : ெந-லிகா> அளG, 3 ேவைள, 1 ம3டல' 
 தK?' ேநா>க : Cர', /ைல 18, வாத ப+த சிர ேராகக, 
டல3ட வா 
 
9. இரச ைதல': 3 
 அளG   : ¼ பல' 
 தK?' ேநா>க : aணாகா> கர<தி, வ+ரண' 
 
10. மமத சி<தாமண+ ேலகிய': 
 இதனா- ேலபன' உ3டா'. 
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BOTANICAL ASPECT 
 
Coccinia grandis Linn 
 
Classification: 
 
 Kingdom : Plant kingdom 
 Division : Angiosperms 
 Class  : Dicotyledons 
 Subclass : Polypetalae 
 Series  : Thalamiflorae 
 Order  : Passiflorales 
 Family  : Cucurbitaceae 
 Genus  : Coccinia 
 Species : grandis 
 
Synonyms: 39 
 
 Coccinia indica 
 Cephalandra indica 
 Momordica monodelpha 
 
Vernacular names: 40 
 
 Tamil  : Kovai kodi, Kovai 
 Bengali : Tala, Kucha 
 English : Ivy guard 
 Gujarati : Gholi 
 Hindi  : Kanduri-ki-bel 
 Sanskrit : Bimbi, bimbika 
 Telugu  : Dondatiga 
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Habit: 
 Perennial, scandent or prostrate, much branched herbs 
 
Leaves: 
 Deltoid or subrotund, angled or lobed, bright green above and pale beneath. 
Palmately 5 nerved from a cordate base with circular glands between the nerves. 
 
Flowers: 
 White large unisexual, dioecious 
 
Male flowers: 
 Solitary or subcymose, calyx tube short and companulate, corolla companulate-5 
petals united stamen 3, non-epipatalous. Filaments connate in a column. Anthers connate. 
Pistillode found. 
 
Female flowers: 
 Solitary, calyx tube short and companulate corolla companulate – 5 petals united, 
staminodes found. Tricarpellary, syncarpous, inferior ovary with parietal placentation, 
stigmas-3 
 
Fruits: 
 Ovoid or ellipsoid with white streaks becoming bright scarlet red when ripe 
 
Seeds: 
 Ovoid, compressed and yellowish-grey in colour 
 
Roots: 
 Long tuberous roots 
 
Varieties: 
 Sweet and bitter 
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Macroscopic characters of the roots: 38 
 The fresh tap root is thick tuberous, long tapering more or less tortuous with a few 
fibrous rootlets attached to it. The roots are flexible, soft and break with a fibrous 
fracture. 
 
Microscopic characters of the roots: 38 
 A transaction of the root shows circular outline and is characteristic of the storage 
type. The parenchyma is full of starch grains and through permeation of parenchyma 
vascular elements are observed. The cork is composed of 6 rows of cells. Phellogen is not 
distinct while phelloderm consists of 3-4 rows of cells. A few scattered groups of 
pericyclic fibres and some stoprage cells are present. The primary xylum is tetrarched, 
pentarched or hexarched in various roots and is readily visible. Near the centre of the root 
it is surrounded by secondary xylum. Occasionally xyloses are found in some vessels. 
Powder of the root is yellowish white in colour. 
 
Chemical constituents: 38 
 Plant shows the presence of ascorbic acid, glutamic acid, asparaginin, tyrosine, 
histidine, phenylalanine, theonine, serine, hydroxyproline, arginine and valine amino-
acids, nicotinic acid and aspartic acid. 
 
 Aerial parts show the presence of cephalandrol, tritriacontane, B-sitosterol and 
two unknown alkaloids named as cephalandrine A and cephalandrine B. 
 
 Roots contain a hypoglycaemic principle. 
 
 Fruits contain fatty acids, taraxerone, taxerol, B-amyrin, lupeol and a bitter 
glycoside containing cucurbitin B. Seeds contain fatty acids. 
 
Action: 
 Alterative, cathartic, anti-spasmodic, expectorant 
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Ethno botany: 38 
 
 Fresh juice from the tuberous root, stem and leaves is given either by itself or in 
combination with certain metallic preparations in early cases of diabetes, intermittent 
glycosuria, enlarged glands and in skin diseases such as pityriasis. 
 
 Leaves mixed with ghee are applied like liniment to sores and skin diseases. 
 
 Leaves are also applied to skin eruptions such as those of small pox, and the plant 
is generally used as tincture internally in gonorrhoea. 
 
 Fresh juice of leaves and stem is useful in bronchial catarrh and bronchitis. 
 
 Leaves boiled in gingelly oil are applied to ringworm, psoriasis and itch. Oil is 
also used as an application to ulcers and as an injection into chronic sinuses. 
 
 Leaves are useful in case of rabies. They are used in sesame oil along with 
camphor and leaves of Adhatoda zeylanica for treating cases of myalgia of chest. 
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MATERIALS AND METHODS 
 
To evaluate the efficacy of “Kovai Kizhangu Choornam” for “Neerizhivu” 
(Diabetes Mellitus) has been selected as per siddha literature, Gunapadam Mooligai 
vaguppu. 
 
Collection of the drug: 
 
 Fresh tubers of kovai were collected from Sholinghur. Its botanical identity was 
authenticated by botany professor of National Institute of Siddha. 
 
Preparation of the test drug: 
 
 The collected tubers were cleaned with water and dried in shade. Then it is made 
into fine powder. It was filtered by a white cloth (Vasthirakayam). 
 
Intended therapeutic use: 
 
 Kovai Kizhangu Choornam in the dose of 1 g t.i.d with luke warm water is given 
for Neerizhivu before meals. 
 
  
        KOVAI          KOVAI KIZHANGU 
 
 
           
 
 
 
 
 
   KOVAI KIZHANGU CHOORNAM 
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BIOCHEMICAL ANALYSIS 
 
     CHEMICAL ANALYSIS OF KOVAI KIZHANGU CHOORNAM 
 
 
Sl. 
NO 
EXPERIMENT OBSERVATION INFERENCE 
1. Appearance of the sample Coarse fine powder  
2. Solubility: 
     a.  A little of the sample is 
shaken well with distilled water 
      b.  A little of the sample is 
shaken well with con HCl / con 
H2So4 
 
Sparingly soluble 
 
Insoluble in Con – 
HCl / Con H2So4 
 
Insoluble 
3. Action of Heat: 
     A small amount of the sample 
is taken in a dry test tube and 
heated gently at first and then 
strongly 
 
No white fumes 
evolved 
 
No brown fumes 
 
Absence of Carbonate 
 
Absence of Nitrate 
4. Flame Test: 
     A small amount of the sample 
is made in to a paste with con. HCl 
in a watch glass and introduced 
into non-luminous part of the 
Bunsen flame 
 
Red colour appeared 
 
Presence of Calcium 
5. Ash Test: 
     A filter paper is soaked into a 
mixture of sample and added 
cobalt nitrate solution then 
introduced into the Bunsen flame 
and ignited 
 
No yellow colour 
flame 
 
Absence of sodium 
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PREPARATION OF EXTRACT: 
 5 gm of Kovai Kizhangu Choornam is weighed accurately and placed in a 250 ml 
clean beaker and added with 50ml of distilled water. Then it is boiled well for about 10 
minutes.  Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml 
with distilled water. This fluid was taken for analysis. 
SL.NO EXPERIMENT OBSERVATION INFERENCE 
I Test for Acid Radicals   
1.  
Test for Sulphate: 
 
a. 2 ml of the above prepared extract is 
taken in a test tube, to this, added 2ml 
of 4% ammonium oxalate solution 
 
b. 2 ml of the above prepared extract is 
added with 2ml of dil. HCl until the 
effervescence ceases off. Then 2ml of 
Barium chloride solution is added 
 
 
 
Cloudy appearance 
Present 
 
 
 
Presence of sulphate. 
 
 
 
 
Sulphate is confirmed 
2. Test for Chloride: 
     2 ml of the above prepared extract is added 
with dil. HNO3 till the effervescence ceases.   
Then 2ml of silver nitrate solution is added 
 
Cloudy appearance 
Present 
 
Presence of chloride 
3. Test for Phosphate: 
     2 ml of the extract is treated with 2ml of 
ammonium molybdate solution and 2ml of 
Con. HNO3 
 
No cloudy yellow 
appearance 
 
Absence of phosphate 
4. Test for Carbonate: 
    2 ml of the extract is treated with 2ml of 
magnesium sulphate solution 
 
No cloudy 
appearance 
 
Absence of Carbonate 
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5. Test for Nitrate: 
    1 gm of the substance is heated with copper 
turning and concentrated H2SO4 and viewed 
the test tube vertically down 
 
No characteristic 
changes 
 
Absence of Nitrate 
6. Test for Sulphide: 
     1 gm of the substance is treated with 2 ml 
of Con. HCl 
 
No rotten egg 
smelling gas evolved 
 
Absence of sulphide` 
7. Test for Fluoride & Oxalate: 
     2ml of extract is added with 2ml of dil. 
acetic acid and 2ml of calcium chloride 
solution and heated 
 
No cloudy 
appearance 
 
Absence of fluoride 
and oxalate 
8. Test for Nitrite: 
     3 drops of the extract is placed on a filter 
paper, on that 2 drops of acetic acid and 2 
drops of benzidine solution is placed. 
 
No characteristic 
changes 
 
Absence of Nitrite 
9. Test for Borate: 
     2 pinches of the substance is made into paste 
by using sulphuric acid and alcohol (95%) and  
introduced into the blue flame 
 
No bluish green 
colour flame 
appeared 
 
Absence of Borate 
II Test For Basic Radicals   
1. Test for Lead: 
     2 ml of the extract is added with 2ml of 
potassium iodide solution 
 
No yellow precipitate 
 
Absence of lead 
2. Test for Copper: 
a. One pinch of substance is made in to 
paste with con. HCl in a watch glass 
and introduced into the non – 
luminous part of the Bunsen flame. 
b. 2 ml of extract is added with excess of 
ammonia solution 
 
 
Blue flame formed 
 
 
 
Blue colour 
precipitate formed 
 
Presence of copper 
 
 
 
Presence of copper 
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3. Test for Aluminium: 
     To the 2ml of the extract sodium 
hydroxide is added in drops to excess 
 
No characteristic 
changes 
 
Absence of aluminium 
4. Test for Iron: 
a. To the 2ml of extract added 2 ml of 
ammonium thiocyanate solution. 
 
b. To the 2ml of extract added 2ml 
ammonium thiocynate solution and 
2ml of con HNO3 is added 
 
 
Mild red colour 
appeared 
 
Blood red colour 
appeared 
 
Presence of Iron 
 
 
Presence of Iron 
5. Test for Zinc: 
          To 2ml of the extract sodium hydroxide 
solution is added in drops to excess      
 
White precipitate is 
formed 
 
Presence of Zinc 
6. Test for Calcium: 
         2ml of the extract is added with 2ml of 
4% ammonium oxalate solution 
 
Cloudy appearance 
white precipitate is 
obtained 
 
Presence of Calcium 
7. Test for Magnesium: 
     To 2ml of extract sodium hydroxide 
solution is added in drops to excess 
 
White precipitate is 
obtained 
 
Presence of Magnesium 
8 Test for Ammonium: 
     To 2ml of extract few ml of Nessler’s 
reagent and excess of sodium hydroxide 
solution are added 
 
No brown colour 
appeared 
 
Absence of ammonium 
9. Test for Potassium: 
    A pinch of substance is treated with 2ml of 
sodium nitrate solution and then treated with 
2ml of cobalt nitrate in 30% glacial acetic 
acid 
 
 
No Yellowish 
precipitate is obtained 
 
Absence of Potassium 
 18 
10. Test for Sodium: 
     2 Pinches of the substance is made into 
paste by using HCl and introduced in to the 
blue flame, of Bunsen burner 
 
No yellow colour 
flame  appeared 
 
Absence of Sodium 
11. Test for Mercury: 
     2 ml of the extract is treated with 2ml of 
sodium hydroxide solution 
 
No yellow precipitate 
is obtained 
 
Absence of Mercury 
12. Test For Arsenic: 
     2ml of extract is treated with 2ml of silver 
nitrate solution 
 
No brownish red 
precipitate is obtained 
 
Absence of Arsenic 
  III.          Miscellaneous:   
1. Test for Starch: 
     2 ml of extract is treated with weak Iodine 
solution 
 
No blue colour 
developed 
 
Absence of starch 
2. Test for Reducing Sugar: 
    5 ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 2 
minutes and added 8 to 10 drops of the extract 
and again boil it for 2 minutes. The colour 
changes are noted 
 
No brick red colour 
developed 
 
Absence of Reducing 
sugar 
3. Test for the Alkaloids: 
a. 2ml of the extract is treated with 2ml 
of potassium iodide solution. 
b. 2ml of extract is treated with 2ml of 
picric acid. 
c. 2ml of the extract is treated with 2ml 
of phospho tungstic acid 
 
 
No red colour 
developed 
No yellow colour 
developed 
No White precipitate 
obtained 
 
 
 
Absence of alkaloid 
 
4. Test for Tannic Acid: 
    2 ml of extract is treated with 2ml of ferric 
chloride solution 
 
No black precipitate 
appeared 
 
Absence of Tannic acid 
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5. Test for Unsaturated 
Compound: 
    To the 2ml of extract 2ml of potassium 
permanganate solution is added 
 
 
Potassium 
Permanganate is 
decolourized 
 
 
Presence of unsaturated 
compound 
6. Test for Amino Acid: 
      2 drops of the extract is placed on a filter 
paper and dried well 
 
Violet colour 
developed 
 
Presence of amino 
acids 
7. Test for Type of Compound: 
2 ml of the extract is treated with 2 ml of 
ferric chloride solution 
 
No green colour 
developed 
 
No red colour 
developed 
 
No violet colour 
developed 
 
No Blue colour 
developed 
 
Absence of oxy quinole 
epineplhrine and phro 
catechol 
Anti pyrine, Aliphatic 
amino acids and 
meconic acid are absent 
Apomorphine salicylate 
and resorcinol are 
absent 
Morphine, phenol 
cresol and hydro 
quinine are absent 
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QUANTITATIVE ANALYSIS 
 
 
 The quantitative analysis of the drug Kovai Kizhangu Choornam was done in 
Mettex laboratories of India, Chennai – 32. 
 
Quantitative analysis: 
 
Aim: 
 
 To determine the metals and minerals in Kovai Kizhangu Choornam. 
 
Instrument: 
 
 Atomic Absorption Spectrometer (AAS) with air – acetylene. 
 
Apparatus and equipment: 
 
 500 ml glass beakers, hot plate, watch glass, 100 ml standard flask. 
 
Chemicals: 
 
 Nitric acid, hydrochloric acid, certified reference standards. 
 
Sample preparation: 
 
 Transfer a weighed Kovai Kizhangu Choornam in to a 500 ml beaker. Add 10 ml 
of 1 + 1 HNO3 and 10 ml of 1 + 1 HCl and heat on a hot plate until the sample gets 
dissolved. Cool and filter to remove insoluble material. Transfer sample to 100 ml 
volumetric flask, adjust volume to 100 ml and mix. Take all precautions to avoid 
contamination at all stages. Prepare a reagent blank containing same amounts of acids 
used in the preparation of sample. Aspirate the standards and sample in to AAS 
instrument as per instrument procedure. 
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Calculation: 
 Percentage of the element = A/B × 100 
  A: concentration of sample in ppm. 
  B: Dilution factor. 42 
 
Physical properties: 
 
Loss on drying: 
 
 Five grams of Kovai Kizhangu Choornam is heated in a hot oven at 40ºC to 
constant weight. The percentage of loss of weight was calculated. 
 
Determination of ash value: 
 
 Weigh accurately 2 – 3 grams of Kovai Kizhangu Choornam in tarred platinum or 
silica dish and incinerate at a temperature not exceeding 450ºC until free from carbon, 
cool and weigh. Calculate the percentage of ash with free reference to the air dried drug. 
 
Acid insoluble ash: 
 
 Boil the ash for 5 minutes with 25 ml of 1 : 1 dilute HCl. Collect the insoluble 
matter in Gooch – crucible on an ash less filter paper, wash with hot water and ignite, 
cool in a dessicator and weigh. Calculate the percentage of acid insoluble ash with 
reference to the air dried drug. 
 
Water soluble ash: 
 
 To the Gooch crucible containing the total ash, add 25 ml of water and boil for 5 
minutes. Collect the insoluble matter in a sintered glass crucible or on ash less filter 
paper. Wash with hot water and ignite in a crucible for 15 minutes at a temperature not 
exceeding 450ºC. Subtract the weight of the insoluble matter from the weight of the ash. 
The difference of weight represents the water soluble ash. Calculate the percentage of 
water soluble ash with reference to the air dried drug. 
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Alkalinity of water soluble ash: 
 
 Five grams of Kovai Kizhangu Choornam converted to ash, boiled with water, 
filtered. Filtrate was titrated against 0.1N of HCl using phenolphthalein as an indicator. 
 
 Alkalinity of water soluble ash = X × St of acid / 0.1 × W 
 
 X = Titre value. 
 
 W = Weight of the material taken. 
 
 Alkalinity is given as ml of 0.1N of HCl equated to 1 gm. 
 
pH: 
 
 Five grams of Kovai Kizhangu Choornam is weighed accurately and placed in 
clear 100 ml beaker. Then 50 ml of distilled water is added to it and dissolved well. Wait 
for 30 minutes and then apply in to pH meter at standard buffer solution of 4.0, 7.0 and 
9.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACOLOGICAL 
STUDY 
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ANTIDIABETIC ACTIVITY OF KOVAI KIZHANGU CHOORNAM IN ALLOXAN 
INDUCED DIABETIC RATS 
 The objective of the study was to evaluate the drug Kovai Kizhangu Choornam 
for antidiabetic activity in normal and diabetic rats respectively.  
MATERIALS AND METHODS: 
Acute toxicity study: 
 The albino mice weighing between 22-28gms were selected to ascertain the 
toxicity range of the test drug Kovai Kizhangu Choornam. The starting dose administered 
to the test group of animals was 100mg/kg. The animals were segregated into six groups 
consisting of six mice each. The increasing doses were administered upto 4000mg/kg. 
The toxic dose was determined by observing the mortality rate in the drug treated groups. 
From this the therapeutic dose was selected for the further study.     
Studies in normal rats: 
Animals: 
 Albino rats (Wistar strain) of either sex weighing 200–300 g procured from 
animal housing facility of Vel’s college were used in the study. Animals were divided 
into six groups each containing five and were provided with standard Pellet diet and 
water ad libitum. They were fasted for about 18 h prior to the experiment, with access to 
water. During the experiment, water was removed while fasting was continued. The drug 
was administered at dose level of 400mg/kg body weight orally to a group containing 5 
animals. A control group was maintained simultaneously and received distilled water 
orally. Blood samples were collected from retro-orbital plexus of each rat before and at 2, 
4, 6 and 8 h after test drug administration and were analyzed for glucose content.  
Preparation of the drug solution: 
 The drug solution was prepared by dissolving the drug in distilled water.  
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Studies in diabetic rats: 
Induction of diabetes: 
 The same groups used earlier (normal) were used to induce diabetes after a 
washout period of 10 days. These animals were injected with freshly prepared aqueous 
solution of alloxan monohydrate (Sigma chemical company, USA) at a dose of 100 
mg/kg body weight by intraperitoneal route.10% dextrose was thereafter administered 
orally to combat the immediate hypoglycaemia that could occur. The serum glucose was 
observed 20 h after alloxanisation. The serum glucose levels were observed daily for 5 
days. The rats showed serum glucose level ranging 280 - 340 mg/dL. Animals were fed 
with the same standard diet and water ad libitum. They were fasted for about 18 h prior to 
the experiment providing access to water.  
 The drug was administered at dose level of 400mg/kg body weight orally to the 
group containing 6 rats. The control group received distilled water only. Blood samples 
were collected and analyzed as mentioned earlier.  
Histo pathology: 
 Animals were sacrificed and the whole pancreas from each animal was removed 
and the small piece was collected in 10% formaline solution and immediately processed. 
Section of 5 mm thickness were cut and stained by Haematoxylin and Eosin (H&E) for 
histological examination. 
Data and statistical analysis: 
 Data were expressed as Mean ± Standard Error of Mean (SEM). The significance 
of blood glucose reduction produced by the drug compared to normal and diabetic control 
was determined by applying ONE WAY ANOVA followed by Dunnet’s multiple 
comparison test. P values of <0.05 were considered to be statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL STUDY 
 25 
நழி 
 
ேவ ெபயக
: 15 
 
 மேமக, இன	
 ந 
 
இய: 
 
 அக சிந ெபவாயாயழித, நழி த இட"தி ஈ, எ
க% 
ெமா&"த, அதைன கா&(சி) சகைர மண வ ச, உட நா-. 
நா% இைள"த எ)0 இய
ைடய. 
 
ேநா வ வழி: 15 
 
 “க)ன மயக"தா க12 ேமகேம” என நா 34, “கிர தி	 

1ணரண ேமக கீ(சக ென)0  )மாகன ததி ெய)0 
பா6சாலி ய)ைனைய க189றாேன” என ம"	 பாரத; 
<றியதா, நழி= ேநா& அள= கட த கலவயா ேமக"ைத" ெதாடர( 
ெச& வேநா& என ெகா%ள	ப2.  
 அ)றி>, மி. உண=, ேசாப" தித, மனகலக, ெபாள) 
ம? மி. த இ(ைச எ)0 இவ9றா4 தா& த ைதய) வழியாக= 
வர <2ெமன அறித ேவ12.  
 ஈத)றி ெந&, பா, க%, இைற(சி, மிக @ைவ>%ள ம?)க%, இன	
( 
@ைவ ெபா திய உண=க% எ)0 இைவக- ேநா& வவழி. 
கவா. 
 
 26 
றிக
: 
 
 சிந ெதள த ந ேபால அக பகணகி இழித4, இழி த 
ந"ளக% ச9 உல) ப@ப@" கா8த4 உட வ)ைம நா-. 
நா% .ைற  ெகா1ேட வத4, நாவறAசி> ஆகிய ;9.றிகைள 
காA2. 
 
ேநாய றிணக
: 15 
 
 ேம9<றிய .றிகைள காA, ந மி. த அளவ இறC.. ந. 
<றிய நிற, மண, நிைற, எைட இவ9%, நிற த1ண ைர	 ேபால=, 
நிைற அள= கட , எைட கன", மண ேத) ேபால= காண	பA2, 
கா&(சி) ேத) மண வ @த4 உ1டா..  
 உட நா-. நா% ெமலிவைட  ெகா1ேட வவட), ேதாலி 
ெந&	
	 பைசய9 வற12 @Cகி கா1பட) ெவ-"த ம6ச% 
நிற"ைத>மைட>.  
 நாவறAசி, மி. த ந ேவAைக, மி. த பசி, 
சி"த ச9 ேநர"தி9.% 
பசிெய2	ப ேபா)ற ேதா9ற உ1டா. ெந&, பா ;தலிய ஊAட 
த ெபா%கைள உ1ண0, உட ஊAட ெபறாைம ;தலிய 
.றிகைள நிைலக( ெச&>.  
 இ ேநா& ெபபா)ைம> ஐய காலமாகிய ;ைமய41டா 
ேநாயா. சிபா)ைம இளைமய4 வவ1டாய0, தக 
ம"வ"தி ேபா. ந2 வயதி உ1டாய0 எளதி தவ12. இ 
தக ம"வ"தி எளதி தராவ) ேநா& ;தி  தன." 
ைணயாக	 பலவைக	பAட ேக2கைள> வவ..  
 27 
 சிந அக மி.  ெவளயாவட) அ உட ச"ைத உகி( 
சகைரயா& ந வழிேய ெவளயாகி வ2.  
 மயக, தைல @9ற, கைள" வ Fத, த) @ரைணயலாம9 
ப2"தி"த, G(@, வயைவ இைவ ேத) மண வ @த, க1 மCக 
அல க1ண திைர>1டாத ஆகிய .ணCகைள காA, மி. த 
அளவ ேபா& ெகா1 த சிநரான, நா-. நா% அளவ 
.ைற  ெகா1ேட வ  நகA2 ேநாைய உ1டாகி, பசிய)ைம, 
ெசயாைம, ஓகாள, வா தி, வய9ேநா&, மனகலக, சின, மயக 
ஆகிய .றிகைள காA	 ப2ைகய கிட"தி G(@" த2மாறி, திணற 
ெச& ெகா4. அல இம, இைர	
, தமரக வா>, நர
" தள(சி 
;தலிய ேநா&கைள" ைண ெகா12 ெகா4. 
 
நா: 
 
 வள நா> அழ நா> < நடகி) ெபமைழயா ஓ2 ந 
ேபால( சிந இறC.. 
 வள நாய) இட பக"ேத ஐய நா < நட தா நழி= 
கா8. 
 நழி= ேநா& ;தி த நிைலய நாக% G) தள  நட.. 
 ப"த நா வைர  நட.மாய) நழி= ேநா& என அறிக. 
 நழி= ேநாய உட வ)ைம .ைற  கா ேமக ேபால பல 
பணக% <), நா தள  வ)ைமய)றி நேரா2த9 ேபா4 அல 
ெந	ப வI த 
I	ேபா4 நாக- 
ர12 நட.. 
 
 
 
 28 
 
MODERN CONCEPT 
 
DIABETES MELLITUS 
 
 Diabetes mellitus is one of the most common endocrine disorders. It is a disorder 
of metabolism of Carbohydrate, Protein and Fat due to absolute or relative deficiency of 
insulin secretion and with varying degree of insulin resistance. This metabolic disorder 
results in long term disease specific microangiopathy and aggravation of 
macroangiopathy. 
 
Etiologic classification: 
 
 1. Type Ι DM – IDDM (Insulin Dependent Diabetes Mellitus) 
 2. Type ΙΙ DM – NIDDM (Non Insulin Dependant Diabetes Mellitus) 
 3. Gestational DM 
 4. Other specific types due to Genetic defects, Endocrinopathies, Drugs or 
Chemical induced, Infections etc. 
 
Clinical features: 
 
 1. Patient is usually obese. 
 2. Polyuria, Polydipsia, Polyphagia, Nocturia 
 3. Patient may present with unhealed wounds, Fungal infections, Pruritus vulva or 
Balanitis. 
 4. Patient may be asymptomatic also. 
 5. Chronic fatigue and malaise 
 6. Paraesthesiae 
 7. Peripheral neuropathy 
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Type ΙΙ DM: 
 
 It is the most common type of DM accounting for 85-90% of the cases. 
 
Pathophysiology: 
 
 The characteristic pathophysiologic abnormalities of type 2 DM are, 
  1. Impaired insulin secretion 
  2. Peripheral insulin resistance 
  3. Excessive hepatic glucose production 
 There are three phases of development. 
  Ι phase – plasma glucose remains normal despite demonstrable insulin 
resistance because insulin levels are elevated. 
  ΙΙ phase – insulin resistance tends to worsen so that despite elevated 
insulin concentration, glucose intolerance becomes manifest by post prandial 
hyperglycemia. 
  ΙΙΙ phase – insulin resistance does not change but insulin secretion 
declines resulting in fasting hyperglycemia and overt diabetes. 
 
Associated disorders: 
 
- Insulin resistance 
- Hyper tension 
- Hyper lipidemia 
- Poly cystic ovary 
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CLINICAL STUDY 
 
Selection of patients: 
 
30 patients of both sexes were selected from the outpatient department of National 
Institute of Siddha. Chennai – 47 by present inclusion, exclusion and withdrawal criteria. 
 
Criteria for selection: 
 
Inclusion criteria: 
 
 The patients selected for clinical trial had the following criteria. 
  1. Age 30 to 70 yrs. 
  2. Willing to attend the OPD once in 12 days for 48 days 
  3. Willing to give blood and urine specimen for the investigation when 
required. 
  4. Blood sugar level Fasting < 150 mg%, Post Prandial < 250 mg%. 
 
Exclusion Criteria: 
 
  1. Blood sugar fasting > 150 mg% and /or PP > 250 mg% 
  2. Patients with diabetic complications like diabetic foot, retinopathy, etc. 
  3. Malignancy 
 
Withdrawal criteria: 
 
  1. Blood sugar level F > 150 mg% and /or PP > 400 mg%. 
  2. Development of Diabetic complications. 
  3. Development of severe hypoglycemia (F < 70 mg %) 
  4. Development of any drug intolerance. 
  5. Any other severe acute illness 
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 The drug “Kovai Kizhangu Choornam” was administered internally in a dose of 
1 g t.i.d. with hot water before food for 48 days. 
 
Analysis: 
 Mean reduction (F & PP) Blood sugar after treatment will be analyzed using 
paired t-test. 
 Mean reduction in proportion (for signs & symptoms) will be analyzed using 
paired X2 -test. 
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RESULTS ANS OBSERVATIONS 
 
Results of biochemical analysis of Kovai Kizhangu Choornam 
 
Table 1 
 
Physical properties: 
 
 
S.No 
 
Parameters 
 
Results 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
 
 
Loss of drying at105ºC, (%) 
 
Ash value at 550ºC, (%) 
 
Water soluble, (%) 
 
Alkalinity as CaCO3 in water soluble ash, (%) 
 
Acid insoluble ash, (%) 
 
pH at 10% aqueous solution 
 
 
0.15 
 
15.39 
 
8.82 
 
3.55 
 
0.25 
 
6.58 
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Table 2 
 
Qualitative analysis: 
 
 
S.No 
 
Parameters 
 
 
Results 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
Calcium 
Sulphate 
Chloride 
Iron 
Unsaturated compound 
Amino acids 
 
Present 
Present 
Present 
Present 
Present 
Present 
 
 
Table 3 
 
Quantitative analysis: 
 
 
S.No 
 
 
Parameters 
 
 
Results 
 
 
1. 
2. 
3. 
4. 
 
 
selenium 
Magnesium 
Zinc 
Copper 
 
 
163.6 mg/kg 
5072 mg/kg 
149 mg/kg 
32 mg/kg 
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RESULTS OF ANTIDIABETIC ACTIVITY 
 
Results and discussion: 
 From the acute toxicity study, I have concluded that the test drug Kovai Kizhangu 
Choornam has no lethal effect upto 4g/kg body weight after oral administration in mice. 
Hence, as per the literature guidelines 1/10th of the dose was fixed to evaluate the anti 
diabetic activity of Kovai Kizhangu Choornam.  
 
 The comparative results of % serum glucose reduction with test drug in normal 
rats were given in Table 1. The comparative results of % serum glucose reduction with 
alloxan induced diabetic rats were given in Table 2. Evidence has been accumulated in 
the past few years supporting that diabetes was precipitated by stress. Additionally, it was 
also reported that hyperglycaemia itself increases stress. The diabetes was induced with 
alloxan, since it was more economical and easily available. Moreover, alloxan was 
reported to produce diabetes by damaging pancreas by free radical related mechanisms.  
 
 Rat was used since it was routinely used animal model for quick screening of 
drugs for their hypoglycaemic/antihyperglycaemic action. Since small amount of blood 
was required for glucose analysis, the blood samples were collected by retro-orbital 
puncture as it was reported to be good method when small samples of blood were 
required. 
 According to the standard working protocol, 14 days daily treatment with test 
drug moderately reduced the elevated blood glucose in alloxan induced diabetic rats 
while it had no effect on blood glucose of normal rats. The antidiabetic activity of Kovai 
Kizhangu Choornam may be attributed to the active ingredients present in the drug. With 
alloxan treatment the blood glucose was raised and it was in the range of 280-340 mg/dL 
in different rats after stabilization period of 15days. Single dose (400 mg/kg body weight, 
oral) treatment with the drug produced 33% antihyperglycaemic effect (antidiabetic 
effect).  
 Finally it can be concluded that Kovai Kizhangu Choornam was found to possess 
moderate (P<0.05) antidiabetic action in alloxan induced diabetic rats.   
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Table 1.Oral glucose tolerance test 
                      Blood glucose (mg/dl) Treatment (Dose / kg body weight) 
Fasting 30 min 90 min 
Normal control 80.5±1.80 158±8.96 233.5±3.92 
KKC (400mg/kg)+Glucose 74.16±1.759* 89.33±2.679** 213±8.06* 
Glibenclamide (0.5mg/kg) 84.16±1.64ns 96.33±2.894** 84.83±1.57** 
Zinc Insulin (4 U) 84.66±1.145ns 89.83±2.242** 86.5±1.258** 
                  Values are expressed as mean ± S.E.M.; n = 6 
                         *P<0.05 VS Normal control 
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Table.2. Measurement of Body weight changes after KOVAI KIZHANGU CHOORNAM 
(KKC) treatment 
 
                          Periodical Weight changes after KOVAI KIZHANGU CHOORNAM treatment  
Drug treatment 
Day0 Day1 Day2 Day4 Day8 Day14 
Normal control 233.3±3.57 234.5±2.51 239.3±2.81 243.1±2.85 245.6±2.14 252.3±1.82 
Diabetic control 211.8±2.94 217±1.91 231.6±2.20 192.1±3.16 194.3±2.34 184.5±4.97 
KKC 400mg/kg 212.3±1.40** 228±1.66ns 214.5±1.40** 218±2.08** 233±1.75* 229±2.13** 
Glibenclamide 
(0.5mg/kg) 216±3.46** 226±1.03* 214.1±2.61** 228.3±1.20** 229.8±2.22** 242±3.25
ns
 
Zinc Insulin 
(4.U/kg) 219.3±3.85* 232±1.83
ns
 222.3±1.49** 219±1.77** 237±4.88ns 238±4.12* 
n = 6; Values are expressed as mean ± S.E.M.;  
aP<0.05 VS Normal control 
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Table: 3. Fasting serum Glucose concentration is normal and Alloxan-induced diabetic 
rats after KOVAI KIZHANGU CHOORNAM (KKC) treatment 
 
Fasting serum Glucose concentration (mg/dl)  measured at 
regular  intervals                 Treatment  
I IV VIII XIV 
Normal Group 72±1.155 72.83±1.249 68.33±1.667 73.5±0.885 
Diabetic Control 398.33±5.2 410.33±10.256 424.33±17.862 395.66±5.251 
KKC (400mg/kg) 97±6.126**b 382±8.66**a 390±10.280a 382±4.22a 
Glibenclamide 
(0.5mg/kg) 75.33±1.764
b
 94.66±1.764b 95.66±1.585b 106±1.932b 
Zinc Insulin (4 U) 72±1.46b 70±1.26b 65.16±1.60b 68.33±1.057b 
         n=6; Values are expressed as mean ±S.E.M 
             *P <0.05 Vs Normal, aP <0.05;  bP <0.01 Vs Diabetic Control 
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Table: 4. Total Cholesterol and Triglyceride levels in normal and Alloxan-induced 
diabetic rats after KOVAI KIZHANGU CHOORNAM (KKC) treatment. 
   n=6; Values are expressed as mean ±S.E.M 
                                             *P <0.05 Vs Normal, aP <0.05;  bP <0.01 Vs Diabetic Control 
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Parameters (mg/dl)  
Treatment 
 
Dose              Total Cholesterol  Triglycerides 
Normal control 10mg/kg of vehicle 83±1.528 93.33±1.606 
Diabetic control - 126.16±1.641 129.16±1.97 
KKC  (400mg/kg) 74.83±1.47**b 72.5±1.54**b 
Glibenclamide  (0.5mg/kg) 84±1.46b 86.66±1.76*b 
Zinc Insulin  (4 U/ml) 73.5±1.89**b 67.33±1.52**b 
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HISTOPATHOLOGICAL STUDY OF PANCREAS SECTION 
 The pancreatic section of the diabetes induced rats showed pancreatic acini with 
small islet with degenerating cells. The groups treated with Kovai Kizhangu Choornam at 
the dose of 400 mg/kg showed pancreatic acini with well preserved pancreatic islet cells. 
In the standard group pancreas showed markedly proliferative (hyperplastic) islets of β 
cells. 
 
Fig – 1. Photomicrograph of rat pancreas in diabetic control animal section showed 
pancreatic acini with small islet with degenerating cells. 
 
  
 
 
Fig – 2. Photomicrograph of rat pancreas in Kovai Kizhangu Choornam treated 
animal section showed pancreatic acini with prominent hyperplastic islet cells 
 
 
 
Fig – 3. photomicrograph of rat pancreas in glibenclamide treated animal section 
showed markedly proliferative islets cells 
 
 
 
Fig – 4. photomicrograph of rat pancreas in zinc insulin treated animal section 
showed hyperplastic islet cells 
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Results of clinical assessment: 
        For the clinical study of Kovai Kizhangu Choornam in Neerizhivu, 30 Patients 
were selected.   
Age wise distribution: 
 
Sex occurrence: 
 No. of patients Percentage 
Male 20 66.66 
Female 10 33.33 
SEX OCCURRENCE
20, 67%
10, 33%
MALE FEMALE
 
S.No Age in year No. of patients Percentage 
1. 30-40 2 6.66 
2. 41-50 6 20 
3. 51-60 16 53.33 
4. 61-70 6 20 
2
20
6
20
16
53.33
6
20
0
10
20
30
40
50
60
30-40 41-50 51-60 61-70
AGE DISTRIBUTION
n o. of patien ts percentage
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Improvement of signs and symptoms: 
 
 
 
IMPROVEMENT OF SIGNS AND SYMPTOMS
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No. of patients  
S.No 
Signs and symptoms 
Before 
treatment 
After 
treatment 
 
Improvement 
1. Polyuria (PU) 20(66.66%) 5(16.66%) 75% 
2. Polydipsia (PD) 21(70%) 6(20%) 71.42% 
3. Polyphagia (PP) 13(43.33%) 1(3.33%) 92.3% 
4. Nocturia (NU) 11(36.66%) 4(13.33%) 63.63% 
5. Tiredness (TN) 17(56.66%) 0 100% 
6. Pain in limbs (PL) 14(46.66%) 7(23.33%) 50% 
7. Pain & burning 
sensation in both 
soles (P&BS) 
13(43.33%) 3(10%) 76.92% 
8. Paraesthesia in feet 
(PF) 
8(26.66%) 1(3.33%) 87.5% 
Polyuria Poly 
dipsia 
Poly 
phagia 
Nocturia Tired 
ness 
Pain in 
limbs 
P&BS PF Pruritus 
vulvae 
Balanitis                        
 S. 
NO 
 
OP.NO 
 
NAME 
 
A/S 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1. AG7263 Nizamudeen 48/M + - + - - - - - + - + - - - - - - - - - 
2. AG8627 Moorthi 44/M - - + - + - - - - - + - - - - - - - - - 
3. AG9093 Mohan 55/M + - - - - - - - + - - - + - - - - - - - 
4. AG9551 Sivachandran 52/M + + + - - - + + + - - - - - + + - - + + 
5. AH120 Lakshmikanthan 58/M + - + - - - - - + - - - + - - - - - - - 
6. AH156 Radhakrishnan 45/M - - + - + - - - - - - - + - - - - - - - 
7. AH2266 Mahantysivadoss 52/F + - + + - - - - + - - - + - - - - - - - 
8. AH2375 Harihara 
Subramaniam 
65/M + - + + + + - - + - - - + - - - - - - - 
9. AH2506 Rajeswari 60/F + - + - + - + + - - + + - - + - - - - - 
10. AH2628 Thirumalai 62/M - - + - + - - - + - + + - - - - - - - - 
11. AH3999 Duraikannan 56/M + - + - - - - - + - - - - - - - - - - - 
12 AH4911 Rahamatullah 64/M + + + + - - + - - - + + + - - - - - + + 
13 AH6436 Premavathi 50/F - - - - - - - - + - - - + - - - - - - - 
14. AH6773 Rajeswari 57/F + + + - - - - - + - + + + - - - - - - - 
15 AH7067 Rukmani 56/F + - + - - - - - - - + - - - - - - - - - 
16 AH927 Narayanan 56/M - - + - - - + - + - + - - - - - - - - - 
17 AH7037 Kadhar 57/M + - - - - - + - + - - - - - + - - - - - 
18 AH7100 Durai swamy 45/M - - - - + - - - + - - - - - - - - - - - 
19 AH7452 Kamala 55/F + - - - + - - - - - + - - - + - - - - - 
20 AH8823 Sundaram 65/M + + - - + - + + + - - - - - + - - - - - 
21 AH8790 Gomathi 65/F + + + + + - + + - - - - + + + - - - - - 
22. AH8897 Venkatesan 58/M + - + + - - + - + - + + - - - - - - - - 
23. AH9067 Paranjothi 53/M - - - - + - - - - - + - - - + - - - - - 
24 AH9944 Shanthi 53/F - - + - - - - - - - + - + - - - - - - - 
25. AI611 Madhavan 68/M + - + - + - + - - - + + + + - - - - - - 
26. AI714 Mahesh kumar 33/M - - - - + - - - - - - - - - - - - - - - 
27 AI743 Jesimma 36/F - - + - - - + - - - - - - - - - - - - - 
28 AH6427 Muruganantham 46/M + - + - - - + - + - - - - - - - - - - - 
29 AH6248 Chandra mohan 58/M + - + + + - - - - - - - + + + - - - - - 
30 AH469 Sagunthala 52/F + - - - - - - - + - + + + - - - - - - - 
 
 P&BS – Pain and burning sensation in both soles, PF – Paraesthesia in the feet 
BLOOD SUGAR (mg%) 
BEFORE TREATMENT AFTER TREATMENT 
                       
 S. 
NO 
 
OP.NO 
 
NAME 
 
A/S 
FASTING POST PRANDIAL FASTING POST PRANDIAL 
1. AG7263 Nizamudeen 48/M 130 160 110 140 
2. AG8627 Moorthi 44/M 120 150 100 140 
3. AG9093 Mohan 55/M 140 180 110 150 
4. AG9551 Sivachandran 52/M 110 180 110 140 
5. AH120 Lakshmikanthan 58/M 130 170 120 160 
6. AH156 Radhakrishnan 45/M 140 190 110 160 
7. AH2266 Mahantysivadoss 52/F 150 220 100 120 
8. AH2375 Harihara 
Subramaniam 
65/M 140 160 120 140 
9. AH2506 Rajeswari 60/F 120 160 110 140 
10. AH2628 Thirumalai 62/M 140 250 130 200 
11. AH3999 Duraikannan 56/M 145 240 130 190 
12 AH4911 Rahamatullah 64/M 130 190 110 130 
13 AH6436 Premavathi 50/F 150 220 120 140 
14. AH6773 Rajeswari 57/F 150 240 120 190 
15 AH7067 Rukmani 56/F 120 190 110 150 
16 AH927 Narayanan 56/M 140 210 110 160 
17 AH7037 Kadhar 57/M 146 190 130 160 
18 AH7100 Durai swamy 45/M 120 190 100 150 
19 AH7452 Kamala 55/F 129 168 110 156 
20 AH8823 Sundaram 65/M 130 190 120 170 
21 AH8790 Gomathi 65/F 150 220 100 160 
22. AH8897 Venkatesan 58/M 134 250 100 180 
23. AH9067 Paranjothi 53/M 124 242 110 170 
24 AH9944 Shanthi 53/F 150 210 112 174 
25. AI611 Madhavan 68/M 108 208 100 170 
26. AI714 Mahesh kumar 33/M 149 247 120 200 
27 AI743 Jesimma 36/F 150 240 110 176 
28 AH6427 Muruganantham 46/M 120 200 110 190 
29 AH6248 Chandra mohan 58/M 110 212 109 170 
30 AH469 Sagunthala 52/F 150 220 130 170 
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DISCUSSION 
 
 The drug Kovai Kizhangu Choornam was selected to find its efficacy in the 
treatment of Neerizhivu. 
 
 The therapeutic efficacy of Kovai Kizhangu Choornam in the disease of 
Neerizhivu is related to exploring its antidiabetic activity through clinical trials. 
 
 From various literatures and informations which strongly support the antidiabetic 
activity of the drug, the author has come to an idea about Kovai Kizhangu Choornam and 
its efficacy in Neerizhivu. 
 
 Biochemical analysis of the drug Kovai Kizhangu Choornam reveals the presence 
of minerals namely, Selenium, Copper, Magnesium, Zinc and Calcium. 
 
Selenium: 
 
 Selenium plays a key role in keeping cell membranes healthy. The pancreas could 
not function properly without selenium. Selenium deficiency causes pancreatitis and 
pancreatic atrophy. 
 
 Selenium prevents lipid peroxidation and protects the cells against the free 
radicals including super oxide. Selenium involved in maintaining structural integrity of 
biological membranes. Selenium as selenocysteine is an essential component of enzymes 
glutathione peroxidase, which protects the cells against oxidative damage by hydro 
peroxidases. Thus it acts as a potent antioxidant. It also facilitates digestion and 
absorption of lipids including vitamin E which is a potent antioxidant. 
 
 43 
Copper: 
 
 It is possible that adequate copper could help prevent dependent diabetes. Copper, 
through its involvement in the formation of several key enzymes involved in the release 
of energy inside the cell and contributes to the function of very many antioxidants, 
assisting the “mopping up” of the free radicals that cause cell damage. 
 
 It protects against free radical damage as a component of superoxide dismutase 
and is needed for Vitamin C to be effective. 
 
Magnesium: 
 
 Magnesium supplementation has been shown to improve insulin sensitivity. 
 
Zinc: 
 
 The zinc content of the adult human body ranges from 1.4 to 2.5 grams, with the 
highest concentrations in the bone, liver, kidney, pancreas, pituitary, prostatic gland and 
muscle tissue. 
 
 Zinc has been associated with a variety of bodily functions such as the healing of 
wounds, reproduction, growth and maintenance of glucose tolerance in the body. 
 
 Zinc is a constituent of insulin. The storage and secretion of insulin from β cells 
of pancreas requires zinc. As a component of many enzymes zinc is involved in the 
metabolism of proteins, carbohydrates, lipids and energy. 
 
 Zinc comprises the structure of copper/zinc-superoxide dismutase (Cu/Zn-SOD). 
Zinc may also have antioxidant activity via its association with the copper-binding 
protein metallothionein. 
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 Zinc assists in maintaining the proper concentration of vitamin E in the blood. 
Zinc is known to have antioxidant properties being a membrane stabilizer, scavenging 
reactive oxygen metabolites and regulating cytokine synthesis. Moreover, the element 
stimulates tissue healing and repair in experimental ulcers directly. 
 
 It may act as a scavenger of radical products through the synthesis of enzymes 
such as superoxide dismutase (SOD) and metallothionein (MT). 
 
Calcium: 
 
 Calcium is important for the release of hormone insulin from islets. In type ІІ 
diabetes there is a defect in neutrophil calcium signaling which results in a lesser increase 
in free cytosolic calcium owing to impaired influx across the plasma membrane. 
Abnormal calcium signaling is likely to be important in the pathogenesis of diabetic 
complication. It may be tantalizing to speculate that pharmacologic modulation of Ca2+ 
levels may improve PMNL (Poly Morpho Nuclear Lymphocytic) function and reduce the 
risk for infection even in patients with persistent hyperglycemia. 
 
Pharmacological studies: 
 
 Pharmacological studies done in Vel’s college of pharmacy, Pallavaram. The 
antidiabetic activity done in Wister albino rats by alloxan induction method. 14 days 
daily treatment with test drug reduced the elevated blood glucose in alloxan induced 
diabetic rats while it had no effect on blood glucose of normal rats. Single dose (400 
mg/kg body weight, oral) treatment with the drug produced 33% antihyperglycaemic 
effect (antidiabetic effect). 
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Clinical assessment: 
 
 For the clinical study of Kovai Kizhangu Choornam in Neerizhivu 30 patients 
were selected.  
 In 30 patients 70% of the patients showed good response to the treatment and 
20% showed fair response. And no adverse effects were observed. 
 
Siddha aspect: 
 
 Neerizhivu is a disease due to derangement of iyya kutram and is followed by 
variations of vali and azhal kutram. Consequently the seven udal thathus also gets 
affected and the patient becomes terminally ill. 
 
 Kovai Kizhangu Choornam has kaippu suvai. 
 
  ”வாத ேமலி	டா மர ள 
  ேசதற ெச சிைறய – ஓதேக  
  கார! வ"கச கா	#$ %ைவெயலா 
  சார ப'கார$ சா()”. 16 
 
 Karppu, thuvarppu and kaippu suvaigal normalize the iyya kutram. 
 From the clinical & statistical analysis, it is proved that the drug Kovai 
Kizhangu Choornam is statistically significant.  
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SUMMARY AND CONCLUSION 
 
 The drug Kovai Kizhangu Choornam has been selected for the study to establish 
its efficacy in the management of Neerizhivu as an important aspect of this dissertation 
work. 
 
 The review of siddha literature about the drug describes the antidiabetic activity 
of the drug. Information about the drug from various literatures was also referred. 
 
 Bio-chemical analysis of the drug reveals the presence of minerals namely 
Magnesium, Zinc, Copper, Selenium and Calcium. 
 
 Pharmacological studies showed that the drug has got significant anti diabetic 
property at the dose of 400 mg/kg and no significant adverse effects. 
 
 From the clinical assessment, it is inferred that the drug has marked response in 
Neerizhivu without any significant adverse effects. 
 
 This is concluded that the drug Kovai Kizhangu Choornam has got significant anti 
diabetic activity, effective in Neerizhivu without causing any adverse effects. 
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INTRODUCTION 
 
 The siddha system is a unique one. The word “siddha” comes from the word 
“siddhi” which means “an object to be attained” or “perfection” or “heavenly bliss”. 
Siddhi generally refers to “attema siddhi” i.e. the eight great supernatural powers. Those 
who attained the above said powers are known as siddhars. 
 
 Man is said to be the microcosm and the world the macrocosm, because which 
exists in the world exists in the man. Further the forces in the microcosm or man are 
identical with the forces of the macrocosm or the world or to put it more plainly, the 
natural forces acting in and through the various organs of the human body are intimately 
related to the similar or corresponding forces acting in and through the organisms of the 
world. 
 This closely follows the siddhars doctrine; 
   “அடதி 	ளேத பட 
    படதி 	ளேத அட 
    அட பட ெமாேற 
    அறி தாபா ேபா” 
- சடன ஞான 
 
 The human body is composed of five elements viz. earth, water, fire, air and space 
(Prithvi, Appu, Theyu, Vayu and Agayam) and is a small world itself, and so the five 
elements lie at the root of the external world and the internal man. They are also found in 
all bodies by the processes of transmutation and union, and the followings are instances 
of such transformed conditions; 
 1. Prithvi  – into bone, flesh, nerves, skin and hair 
 2. Appu  – bile, blood, semen, secretion and sweat 
 3. Theyu – hunger, thirst, sleep, beauty and indolence 
 4. Vayu – contraction, expansion and motion 
 5. Agayam – interspaces of the stomach, heart, neck and the head 
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 Siddhars school fully recognizes 96 thatvas and further add that the human body 
is composed of 72,000 blood vessels, 13,000 nerves, 10 main arteries, 10 vital airs 
(prana), all together in the form of a network, and it is owing to the derangement of the 
three humours (Vatha, Pitha, Kapha) becomes liable to 4448 diseases. 
 
 The three humours maintain the upkeep of the human body through their 
combined functioning. The normal ratio of Vatha, Pitha and Kapha are in the proportion 
of 1: ½: ¼ respectively, when deranged they bring about diseases particular to their 
influence and when one or the other of the humours combine in such a way as to get 
deranged by aggregation, diminution etc. disease or death may be the result. 
 
   “மிகி! ைறய! ேநா%ெச%& 'ேலா 
   வளதலா எணய ,-” 
      - தி.வ	/வ 
 
 The disease Keel Vayu is due to the derangement of the Vatha humour and the 
disease Azhal Keel Vayu is due to the derangement of humours Pitha and Vatha. This 
disease has the symptoms like joint pain, swelling, tenderness, limitation of movements 
and even immobility especially in elders. 
 
 The drug Shanmuga Mezhugu has been mentioned in siddha literatures to be 
effective in the treatment of Azhal Keel Vayu. Shanmuga Mezhugu contains Veeram, 
Pooram and Lingam as its main ingredients and these three has the property of 
neutralizing the Vatha humour and subsequently the Pitha humour. So, in this 
dissertation the author has to evaluate the anti-inflammatory, analgesic and antipyretic of 
Shanmuga Mezhugu. 
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AIM AND OBJECTIVE 
 
Aim: 
 
 The aim of the dissertation is to evaluate the efficacy of Shanmuga Mezhugu for 
Azhal Keel Vayu. 
 
Objective: 
 
 Azhal Keel Vayu is the most common joint disease of human and leading cause of 
disability in elderly and it has become a challenging problem to find out a permanent 
solution for this disease. Even though many anti-inflammatory, analgesic and anti-pyretic 
drugs are there in conventional medicine, they are only time being and have side effects. 
This urged the author to find a safe and easily available drug, which is not having any 
adverse effects. 
 
 Since, no analysis has been made so far in Shanmuga Mezhugu for the disease 
Azhal Keel Vayu. So, the author has selected the drug to prove its efficacy on the same. 
 
 The efficacy of Shanmuga Mezhugu has been evaluated in following aspects: 
 
• Collection of literary evidences in Siddha aspect. 
• Gunapadam aspect 
• Botanical aspect 
• Biochemical analysis 
• Pharmacological analysis 
• Clinical assessment 
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GUNAPADAM ASPECT 
 
வ ர 
ேவ ெபயக
: 
  “வ ரதி ேபதைனேய வளபேக 
   வளகியேதா திற திறமா 
  மாரமாமதி ெவைள ெச ரமா 
   மாகான வாதிக ெக!பமா 
  வாரமா வகாரதி தைலவனா 
   மன#யேதா $வ% த ேசவகனா 
   ரமா மைலகள#ேல உ!பவத 
   'யபான வ ரதி ேப(மாேம”. 1 
       பா. எ*:211 
 ம+னா,ிைமத, ெகா-சிவ ர, $வ%, ேசவக, சர- '*ண, 
பறகி/ பா,ாண, சாரதி ச%(, பறி மி%( 
 
சவ ர ெசைற: 3 
  
 $ர 80, கறி0/1 80, %(' 40, ப2கார 20, ெபா324/1 20, $ந6 
20, அனேபதி 10, நவ-சார 5 பகளாக இைவகைள நி6ெத9%, 
அைர% /பயலி39 :2, சீைலம* ெச<% எ=%, இறகி ள#த 
பற பாைவய3டா? :2ேம? அைடயா< வ ர ப2தி(. 
 
ைவ: 
  
 கா/1, உ/1 
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வ ய: 
  
 ெவ/ப 
 
ப: 
  
 கா/1 
 
ெசைக: 
  
 உட? ேத!றி, கி(மி நாசின#, அ@கலக!றி, 1*A*டாகி 
 
ெபாண: 
  
  “மெமா9 3ட ெகா2யவன# லதிர39 
  %மா கிச/ெப(கB Cைலேநா< Ð வைம06 
  காமிய/1* ணாதியேநா< க*டா!சD 
  வ ரெனB சாமிநா மைத0- ச=”. 30 
   
  சDவ ரதி நாமைத உ-ச=தாேல ம, ைறேநா<, 
தைக வைளவகிற மகா வாதேராககள# E3ட, %மாமிச வள-சி, 
Cைல ேநா<க, வைம ெபா(திய ெப* ேபாகதினா? வைளகிற 
(ெகா6, அைரயா/1 Fதலிய) 1*க ஆகிய இைவ ந. 
  இதைன பலவைக/ப3ட க*ேணா<க 
உபேயாகிகிறன. 
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தி ைறக
: 
  
 ஒ( பல வ ரக32, மிள 2ந வ39 ஆ6 மண ேநர 
'( ெகா9%/ பற மிள க!கதி! ைவ%, ஒ( பா*டதி? 
அைர/ப2 கறி0/1ட ஒ( பல Cடைன கல% அத! ேம!ப2 
வ ரைத/ 1ைத%- சில மண ேநர சி6 தயா? எ=% எ9/ப%. 
  
 இளந=? சிறி% Cடைன கல% ஒ( பாைனயலி39, வ ரைத 
%லாயதிரமாக ந=? படாம? அைரமண ேநர எ=% எ9த?. 
  
 ப2கார ஒ( பல, Cட ஒ( பல இர*ைட0 ெபா2% 
ைவ% ெகா*9, வ ரக32 ெகாBச ெகாBசமா< கிராச ெகா9% 
எ9த?. 
  
 சDவ ரைத ஒ( பIகான#லி39, அ% F@ப2 Fைல/பாலி39, 
பா? F@வ% '*9 வைர ெவ<யலி? உலதி எ9% ெகாள?, 
Fைல/பா4/ பதி? ப'வபாைல உபேயாகி/ப% உ*9. 
  
 பாக!காைய/ பள% ந9வ? சDவ ரக32ைய ைவ% கய!றா? 
க32, %லாயதிரமா< ந=? F@காம? இளந அ?ல% பழ-சா!றி? ஒ( 
மண ேநர எ=% எ9த?. 
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வ ர ேச வாதேநாகான மக 
 
1. சட மாத ெச
ர 
2. வஜிர க மாதிைர 
3. வ ர ெச
ர3 
4. வ ர ெம 
5. வ ர மாதிைர 
6. அயவ ர ெச
ர3 
7. தி த ெம2 
8. அயகா
த சடமாத ெச
ர 
9. சக தள ெச
ர 
10. இரச ெம 
11. இல இரச பத#க 
12.  ைற பத#க 
13. நமசிவாய ெச
ர 
14. வ ர ெச
ர 
15. ப&சா'கின) ெச
ர 
16. வ ர ெம 
17. மகாவ ர ெம3 
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வ ர ந 	றி	ண 
  
 இஃ இரததி	 வைரவ	 கல வடைத வைரவ	 
வைளவ. இதனா	, கள ைவ, வா நற	, வா, 
ெதா"ைட, ஆமாசய இைவ வ 'கி( "ணாத	, வாதி, ேபதி, இரத 
ேபதி, எசி	 வ-'கெவா.டாம/ப0 ெதா"ைட ேநாத	, 1க வ 'க	, 
ேதா	 ெவ0 சிைல ந2 வ0த	, பகவலி, தாக, வக	, மயக, 
32ைச, வலி 1தலியன4 உ"டா. அ7றி மரண1"டா. 
 
றி: 
  “1ைறயாக ச8வ ர ெமாழலா ெகா"டா	 
  சி:ெந;<சி/ சா:"ண த; Ð அைறயேக= 
  நலிேவ ராேம ெநச.0 சாறாேம 
  பாலி ெத7ன' க=> பக2”. 
 சி: ெந;<சி/ சா:, நலிேவ2(ப.ைட க	க, ெநச.0 
கீைரசா:, ெத7ன'க= இைவகளெலா7ைற ந<சி7 வ7ைமதத 
அளவ	 ந< 1றிம.@ ெகா@க ேவ"@. 
 ேகாழி1.ைட ெவ"க;ைவ த"ண 2 அ	ல பாAட7 கல 
அ0க0 ெகா@ வதாA, இளந2 அ;தினாA வ ரதி7 ந< ந.  
 இதைன, 
  “அ"டதி7 ெவ"க;ைவ யாவ7பா லி/கல 
  "@வர வ ரBர மகA' Ð க"டCவா 
  ஏண/ெகா0ேய யளந ர;தி@B 
  மாண( ெப;ைம வ-”. 6 
 எ7ற க;Eரா2 த"டக ெசளா	 அறியலா. 
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ர 
 
 ெதாைக ற	பட 64 பாடாணக காண	படாதி, ர 
பாடாண வைகக ஒறாகேவ கத	பகிற. இ இரச, உ	  
இைவகள" #னா% ெச&ய	பகிற சர(கா). 3 
 
ர ெசைற: 
  
 ஒ பா*ட+தி% 16 வராகெனைட கதக ைவ+ உ(கி, 80 
வராகெனைட இரச ேச,+ ழாவ.( ெகா*#தா% க++ 
/ளாகிவ.. ப.ற) ேவெறா பா*ட+தி% பாதி()0 ெசக% ெபா#ைய	 
ேபா அதேம% அைர	ப# கறி3	ைப ைவ+ உ	ப. ேம% ேம4ப# 
இரசகதிைய ைவ+ சீைலம* ெச& 12 மண. ேநர காடா(கின"யா& 
எ9+( )ள",த ப.ற) ேம%பா*ட+ைத சா(கிரைதயா& ந:(கி	 பா,+தா% 
ர க#யா&	 ப#தி(). 3 
 
ைவ: 
  
 உ	 , கா,	 . 
வ ய: 
  
 ெவ	ப 
 
ப: 
  
 கா,	  
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ெசைக: 
  
 உட% ேத4றி, கிமி நாசின", உமி;ந:, ெப(கி, கைம ேநா&கைள 
சமன ெச&ய(#ய தைம, ேபதிைய உ* ப*< )ண, ப.+த ந:ைர 
அதிக	ப+ )ண. 
 
ெபாண: 
  
  “இைடவாத =ைல ெய9=ைல )ம 
  ெதாைடவாைழ வாதமா> ேசாண. Ð ய.ைடயாேதா 
  ெவா()ரச க,	ர ெமாேற யளேவாந% 
  இ()ெவ%ல+ ேத?நா ள :”. 
   
 ந%ல இரச க,	ர+ைத அள@ட க  ெவ%ல+தி% 7 நா 
ெகா(க, இ	ைப	 ப4றிய =ைல, ஆகா) எ90சைல+ தகிற =ைல, 
வாத )ம, ெதாைட வாைழ, வாதர+த ேநா& Bதலியன த:. 
 
தி ைறக: 
  
 கமாC ெவ4றிைல, மிள) இர*ைட3 கா%பல வ :த 
நிC+ெத+0 சிறி ந:, வ. அைர+, க%க+ைத ஒ ப# ந:9% கல, 
ஒ பல ர+ைத0 சீைலய.% B# லாயதிரமா& ந:9% அமி?ப# 
ெச&, சிC த:யா% எ9(க ேவ*. ந:, B(கா% ப) D*#ய ப.ற), 
ர+ைத எ+ ந:,வ.( க?வ. ெவ&ய.லி% உல,+தி எ(க0 D+தியா. 
  
 57 
 
 ஒ பல ர+தி4) Bைல	பாலினா% 3 மண.ேநர D()( 
ெகா+	 ப.ற) ெவைள	 *+ ைதல+தினா% 9 மண. ேநர 
D(கி எ+( ெகாள@. 
 
 இேலகியகள"% ேச,(க ேவ*#ய ர+ைத, BDBD(ைக0 
சா4றினா% D(கி( க?வ@. 
 
ர ந றி ண: 
 
 ர வ.டமி+தா% Bக+தி% ெசEவா	 	 ேபால Bக	ப, ேவ,() 
அதிகமா& உ*டாத%, மா,ப. பள+தி% ப(க#	  *ண.ரண 
கா<த%, ப(க+தி% வலி, வாய.% கார படாத ப#  *ணாத%, பFச வ :(க, 
உ*ணா(கி% வ.ரண, ேபதி, இர+த( கழி0ச% Bதலிய ,()ணகைள( 
கா*ப.(). 29 
 
றி: 
 
 நில	பைன( கிழ), வ%லாைர ேவ,, ெபானாகாண. ேவ,, க* 
பாரகி ஆகிய இைவ ஒEெவாC தன"+தன" கா% பல எ+ ஒC 
ேச,+( )#ந:9, இ ேவைள வ :த இர* அ%ல GC வார 
ப+திய+ட அத ந:). 
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ர ேச வாதேநாகான மக 
 
1. ர க3 
2. ர மா
திைர3 
3. கர சிதாமண மா
திைர 
4. ைல இராச மா
திைர28 
5. இரச கர பப27 
6. ர சரச பப23 
7. சட மாத ெசர 
8. தித ெம2 
9.  பத க 
10. !ைற பத க 
11. வ $ர ெம2 
12. ராமபாண ெசர 
13. உலேகா
தம ெசர 
14. நமசிவாய ெசர 
15. அயகாத சடமாத ெசர29 
16. ச!க தள+ ெசர23 
17. மகாவ $ர ெம3 
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இலிக 
ேவ ெபயக
: 3 
 ஆறி, இலிக
, இராவ
, கைடவன கப
, கலிக
, 
காசன
, கரண
, சடக
, சமரச
, சானய
, ெசர
, மண ராக
, 
மிேல"ச
, வன, வன. 
 
பக
: 
 கன# தைம%
, ெந'ப லிட (ைக% தைம%
, ந)*+ கைரயா# 
தைம%
 உ-. 
 வாசைன%
, உ'சி%
 கிைடயா.. 
 
வ ய: 
 ெவப
. 
 
ெசைக: 
 உட+ ேத/றி. 
 
ெபா ண: 
  “ேபதி0ர சன ெப'வ ரண ந)ெரா-த 
  காதக1 காச கரபா( Ð ேணாத 
  2'வ லிக சகதமா 3'க41 %
ேபா 
  'வ லிக சகம#ைத ெகா5”. 30 
 
  “ஆதி ய ரத2' காதலா/ சாதிலிக 
  ேமாதி லிரதண 6/7டலி/ ற).(* 
  4ட கிரதி ெகா-8ைல வாத6த 
  94ட ேநா:கைளேயா4 -
”. 
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 ேபதி, 0ர
, சநிபாத
, த)ரா(க5, அதி=#திர
, காணாக1 வ ட
, 
காச
, கரபா, சிர, >ணாகா: கிரதி, 4ட
, கிரதி, ெகா-ைம 
ெச:கிற 8ைல, வாத ேநா: 6தலியைவகைள%
 ம/7
 உடலி+ 
மைற. இ'
 ப ண கைள%
 ந)
. 
  “இலிக" சரெகாேற சரெக+லா மிைறயா
 
  ேமகவைக வ ைன நமனான லிக
”. 
 எற அ1யா+ சரக@ெக+லா
 இலிக
 இைறெயன2
, ேமக 
ேநா:க@ நம என2
 அறியலா
. 
 
தி ைறக
: 
 பழ"சா7, ப0
பா+, ேமன"சா7 இ
=ைற%
 சமெவைட B41 
இலிக#தி/ 0'கி4- எ-க 0#தியா
. 
 
 6ைலபாலி9
, எ9மி"சகன இரச#தி9
 6ைறேய ஒDெவா' 
நா5 ஊறைவ#ெத-க 0#தியா
. 
 
 அழிசி/ ப4ைட ஒ' வ )ைசைய ந7கி இ1#. நா ப1 (ள#த 
கா1ய + ேபா4- இர2 பனய + ைவ#., ம7நா5 காைல நறா: ப ைச. 
கலகியதி+ ஒ' பல
 இலிக#ைத சீைலய + க41ய 4-, ேம+ச41 =1 
சீைல ம ெச:. உல#தி ப ற பனய + ைவ#ெத-#., அ-ேப/றி 
வ ள ேபால ந) வ/7
ப1 எ4-" சாம
 எ*#., எ-#.# .ைட#. 6 
ேபாலேவ, (ளக'ைண" ச=ல
 கலத கா1 ந), நனா* ேவ கலத கா1 
ந) இDவ ர19
 தன#தனயா: எ*#ெத-க" 0#தியா
. 5 
 
 க41யாக உ5ள சாதிலிக#ைத கர1ய + ந+ெலெணய லி4-" 
ச/7 ெகாதிக ைவக2
. ப  இர4ைடம1 சீைலய + ேதாலாயதிரமாக 
க41 ேகாமய#தி+ ேவகைவ#. எ-#. ெகா5ள 0#தியா
. 
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இலிக ேச	 வாதேநாகான ம	க 
 
1. ேமகராசாக எ
ெண32 
2. இலிக க32 
3. சவ ேமகேராக க
டன கா
ப ைதல33 
4. வ ர ெம 34 
5. இலிகக ெச!"ர28 
6. அ$ைவ லிக ெம 23 
7. இலிக ெசாண ெச!"ர 
8. சீன லிக ெச!"ர 
9. இலிக& '
ண 
10. இலிக( பதக 
11. மாதா
ட ைபரவ 
12. வ ர& ெச!"ர 
13. உ*திரவா+ லிக மாதிைர23 
14. ஆன!த ைபரவ ரச25 
15. ேமகனாதி  ள.ைக24 
16. /ர ெம 35 
17. உ*  மாதிைர35 
18. சிதா!த ைபரவ மாதிைர36 
19. ேவதா!த ைபரவ மாதிைர36 
20. இலிக ெச!"ர20 
21. இலிக ெம 20 
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இலிக ந	
 றிண 
 
 வாய, உணா	, 	ரவைள, ெப	ட தலியன ெவ 
பணாகி ப தி!ைவ கசகி ெவய#லி இ%டா& ேபாலி	. 
வாய# கார பட யா. 29 
 
ந றி: 
 
 சாதிகா(, வாமிள	, ெசப தி ேவ*ப%ைட, க&க+ 
இைவகைள  தன, தன, ஒ.ெவா வராகெனைட எ+  ைறப 
	ந23%+ இேவைள ஒ மடல அதி வர5. 29 
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 (Zingiber officinale) 
 
ேவ ெபயக
: 
   “ட ேப
 தைனேய ெசாலேக 
    யாகா வ த வவமா 
   ட நாகமா ேபஷமா 
    கிரமா க#ப$திர% சி&கி' ேப
 
   நகிட தா$தி(ப% சாதக மா 
    சாகமா )ற+மா கச+மா 
   பகிட$ திறிேதாஷ மான,யா 
    ப(பாைஷ நாமெமலா% காேம” 1 
        பா. எ:699 
 அ/க', அதக, ஆ
$ரக, உபல, உல
2த இ%சி, க4 ப$திர, 
, ெசா, ெசௗப'ன, ெசௗவ
ண, நவ&, நாகர, மெநௗஷத, 
வ7வேபஷஜ, வட9ய அமி
த, ேவ
ெகா+. 
 
பயப உ: 4 
 கிழ (உல
2த;) 
ைவ: 
 கா
+ 
தைம: 
 ெவப 
ப:  
 கா
+ 
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ெசைக: 
 ெவபடாகி, பசி$த$<, அக=4வா>வக#றி 
 
ண: 
 கினா ெச(யாைம, மா
ெப(7ச, +ள,ேயப, ெவப, கீAவா> 
ேநா>, இைர+, இ/ம, கழி7ச, நேர#ற, 'ம, வய#&பச, 
கா;$த, க ேநா>, தைல ேநா>, ைல வலி, பா4, வய#&$த 
ேபா. 
 “Bைலம2த ெந%ெச(+ ேதாடேம பமழைல 
 9ல இைரப/ம 9ன 
 Ð வாலகப 
 ேதாடமதி சார2 ெதாட
வாத 'மந
$ 
 ேதாடஆ மேபா% ”. 9 
 
 “வாத பணவய Cத# ெசDவா> 
  வலிதைல வலிைல வலிய/ வழிந
 
 சீத$ ெதா4வ( ேபதி பலேரா 
  சிகமலி கமக கமி கபமா
 
 சீத7 ரவ( ேபத7 ரேநா> 
  ெதறிப4 ெமனெமாழி வ
+வ தன,ேல 
 ஈ; தFமி த; தவா 
  ெதவதி யைலநவ &ண னேவ”. 8 
 
தி: 
  ஓ
 எைட,  இர4 எைட ணக ேச
$;$ 
தாள,$;, ஒ/ ஜாம ெச'ற ப' கIவ உல
$தி ேம ேதாைல7 சீவ 
கழிக ேவ4. 28 
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 ேச வாதேநாகான ம#$க
: 
 
1. ப%ச தபாகின, ேலகிய20 
2. அவ ப$தி7 Bரண21 
3. ெசௗபாகிய  ேலகிய19 
4. றி%சி எெண>17 
5. லன பJ$ ைதல17 
6. ப%சா
க$ ைதல17 
7. தச9ல மாஷ$ைதல17 
8. வாத ரா=சத7 Bரண17 
9. Kரணாதி7 Bரண18 
10. கி Bரண18 
11. மாஷ$ ைதல18 
12. ெகாேவலி ெந>18 
13. அசன வவாதி ைதல18 
14. சி#றா=$ ைதல18 
15. கனகலிக ெமI24 
16. சிகாமண Bரண27 
17. மஹா அவக2தி ரசாயன26 
18. ஓஷாதிபதி ேலகிய26 
19. ஆன2த ேகாடாழி மா$திைர24 
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ஏலசி 
 
ேவ ெபயக
: 
 
  “ஏலதி ேப
தைனேய யயப ேக 
   ெயத ேயமதிர வசகா ேதவமா 
  லமா டக ேகாலக 
    லியா திறி"டா திறிதிேவ
 #$மா 
  வாலமா வகிர ெகத ரசமா 
   வளமான பேறா&சிய ேதச பதிைர 
  காலமா' காறண கா&ச)"டா* மா' 
   கா+யமா ேமலதி கணமாேம”. 1 
       பா.எ-:749 
 ஆசி, ேகார'க, #. 4 
 
பயப உ: 
 கா/, அ+சி. 
ைவ: 
 கா
)". 
 
தைம: 
 ெவ)ப 
 
ப: 
 கா
)". 
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ெசைக: 4 
 
 ெவ)ப1-டாகி, அக23வா/வக4றி, பசித5-#. 
 
ண: 
  “ெதா-ைட வா/க*6 தா7 த'கள8  
   ேதா9 ேநாயதி சாரப ேமகதா  
  உ-ைட ேபா எ<' க2# கி+&சர 
   உழைல வாதி சிலதி வஷ?ர 
  ப-ைட ெவைக வதாகேநா/ காச1 
   பா< ேசாம) பணவ ந2ட1 
  அ-ைட ய@ைளவ பத இைவெக லா 
   ஆல மா'கமB ஏல மCதேத”. 8 
 
  “வக  ெபCவாதி ெவ/யவழ  ந5
)ேபதி 
  மிகெவ< பத மிமயக Ð சிக74ற 
  மத வய49வலி மாேத வைரேதா3 
  அத19 மாசி கறி”. 
 
 ஏலதா  வக , வாதி, ேமககா'ைக, ந5
ேபதி, பத மயக, 
மத, வய49வலி 1தலியைவ ந5'. 
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ஏலசி ேச வாதேநா"கான ம$%க
: 
 
1. பச த5பாகின8 ேலகிய20 
2. அவபதி& ரண21 
3. பC'காமலக ைதல17 
4. எCெக-ெண/17 
5. கC'ேகாழி& ரண18 
6. கி  ரண18 
7. அDவகதாதி ேலகிய18 
8. க-ட'காலி ேலகிய18 
9. அசன வ வாதி ைதல18 
10. சி4றா12# ைதல18 
11. நவக-ட ைதல18 
12. பர'கி)ப2ைட ரசாயன26 
13. தி)பலி ரசாயன26 
14. மஹா அ?வகதி ரசாயன26 
15. வா$ கீலக ேலகிய26 
16. ஓஷாதிபதி ேலகிய26 
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கிரா 
 
ேவ ெபயக
: 
 
  “கிராட	 ேபதைனேய கதிேக 
   கடலய டமா கா ள 
  ேதறா மல வக மா! 
   சிகர ேகவலமா! சிவச#தன $ப 
  வறா வாகி% சப& $பமா 
   வா'த சின(யா ம) பாகி*சி 
  தறா தாகசமின(' தளமா! ச'தி 
   சதிரான கிராெப,! சா'தலாேம”. 1 
       பா.எ.:750 
 அ!க, உ1கட, கவா2 கிரா, ேசாச, திரள(, வராக. 4 
 
பயப உ: 
 3 
ைவ: 
 கார, வ,வ,	. 
 
தைம: 
 ெவ	ப 
 
ப: 
 கா	. 
 
 70 
ெசைக: 4 
 இசிவக1றி, அக5வா2வக1றி, பசி'த6'7.. 
ண: 
  “ப'த மயக ேபதிெயா5 வா#தி8ேபா 
  'தவர' தக5	# ேதா,ேமா Ð ெம'த 
  இலவக ெகா.டவ ேக1 கமா 
  மலமேக க5ெமன வா9':”. 
 
  “கிலந டகண =வயக லா!சன#தா 
  சிக>வடா* சவா சிய	பண8 Ð மகி 
  டக	 3ேவா5 த%பட# ேதாறிலி> 
  வக	3 ேவா5ைர': வா”. 9 
 கிரா மயக, ேபதி, வா#தி, திகழி*ச>, நாபட கழி*ச>, 
எவா2க5	, ெசவேநா2, சிவ#த ம*ச, க,'த ம*ச, க.ண> 3, 
பைடக@ ஆகியவ1ைற ந6. 
 
கிரா ேச வாதேநா!கான ம#$க
: 
1. றி!சி எ.ெண217 
2. எெக.ெண217 
3. அBவக#தாதி =ரண18 
4. இலவக	ப'தி% வடக18 
5. மான ப'தி% வடக18 
6. க.டகாலி ேலகிய18 
7. சி1றாC' ைதல18 
8. மாஷ' ைதல18 
9. நவக.ட' ைதல18 
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ேத 
 
ேவ ெபயக
: 
 
  “ேதைடய ேப	தைனேய ெசப ேக 
   ெசகபான மவா ஷதிடமா 
  மானநிற மாசிதமா சப ரஷ "மா 
   மா#மா சனமா $%பரச மா& 
  தானட தய லவ	ண ம$மா 
   )ப திற& #ப லி* கமி+த வ	ணமா& 
  ஊண லிட உ.கினமா ெம/மா 
   ஓதியேதா	 ேதனட நாமமாேம”. 1 
       பா.எ2:390 
 
ெசைக: 
 உ3ளழலா6றி, மலமிளகி, வ	ப , அ/கலக6றி, ேகாைழயக6றி, 
ேபாஷணகா8, 9க"2டாகி, பசித:92;. 3 
 
ண: 
  “ப த"ட< வா&தி ப 8யாத ெதா&தகப 
  எதிவ. வா= மிற*கிேபா Ð ெமதேம 
  ஊன>+ ரதமைற ?6றப; #திெச=? 
  ேதன< ெபாணேம ெச$”. 31 
 ந@ல ேதனா@ ப த, வா&தி, கப சப&தமான ேராக*க3, வா?, 
இரததி>3ள 6ற*க3 ந:*. 
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ெகாேதன ண: 
  “வாதப த ைவயைத மா6+"ள மா&ைததைன 
  காதெமன ேவாட க;?*கா2 Ð Bதரமா 
  வ$"ைல மாேத வ.ம.சி ந:கிவ C* 
  ெகா$ேத ந<றா* D+”. 31 
 ெகா$ேத< தி8ேதாஷ, உைளமா&ைத, அேராசக இவ6ைற 
ந: 
 
மைலேத: 
  “ஐய .ம லFைளவ க லகி$2 ெவ$ட@ேநா= . 
  ைபய ெவாழி? பசி?"+ Ð ைவயகதி@ 
  ெப2Gமிைச யாம.&தி6 ேக6ற வபான 
  ந2Gமைல ேதெனா<றி னா@”. 31 
 மைலேத< #வாச, வ க@, க2வ ரண, #ர, ேதக கC$ 
இவ6ைற ந:. த:பன", ந@ல ெதான? த.. இ 
அபான*கத. 
 
மரெபாேத: 
  “பசிெவபா வா&திம&த ப@வ க@ ெவ=ய 
  .சி" கப&9ல ேராக* Ð கசிவகலா 
  ெகா&ேத< பாC* ழலண*ேக காவ <மர 
  ெபா&ேத 2டாய 6 ேபா”. 31 
 மரெபா& ேதனா@ பசி, உ%ண உ2டா. வமன, ம&தாகின, 
வ க@, அேராசக, இ.ம@, #வாச, )ய, அதி9ல ேராக ேபா. 
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மைனேத: 
  “$2G $ைர?ேபா ேபாகா கரபன+ 
  ெம2ண8ய த:பனமா ேம&திைழேய Ð க2Gகள6 
  BHசி$/ ெவCகப ெபா@லா வ .மல+ 
  ேபHசி<மைன ேத ேப#”. 31 
 
 வ :Cகள6 கCகி<ற ேதனா@ பசி உ2டா. வ ரண, கரபா<,  
ேநதிர வ ரணகி.மி, $/ ெவC, சிேல%ம ேகாப, காச ந:*. 
 
ேத: 
  “ெகாபண ? மாேத வலய ெள@லா	 
  ெமாபநி<ற ைவய ெமாழி*கா2 Ð ெகாபள* 
  காச#வா சவா&தி க2ண ெல/ ேநா=கள+ 
  வ :#$6+ ேத ெம=”. 31 
 
 $6+ேதனா@ கப ேதாஷ, இ.ம@, ஈைள, ச	தி, ேநதிர ேராக 
ந:*. 
 
திய ேத: 
  “ஆ?ட ;னம ேராசி யககப" 
  ேமய வழவன	& ேத+*கா2 Ð 9ய 
  மதிய ெமவதன மாதரேச நா 
  $தியந+& ேதனா6 $க@”. 31 
 
 $திய ேதனா@ நிைற ஆ?3, சKர ெவப, ேதஜ# உ2டா. 
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பைழய ேத: 
  “வாத ெப.ைக வய 6ெற8ைள த&ைறையH 
  ேசத பறிமி< ெசபேவ Ð மாதரேச 
  சதி $+மரச& த<ைன92 C$ள$ 
  திதி $+பைழய ேத<”. 31 
 பைழய ேதனா@ வாத ேராக, வய 6ெற8Hச@, வாத Mல ேராக 
உ2டா. 
 
!தி: 
 இதைன உபேயாகி"< ந:	 இய&திரதி@ ைவ கா=HசிH 
Nடாய . ேபாேத ஈர கபள ண ய @ வ C வ;க; ெகா3ள 
ேவ2C. 
 ஓைடH #C ேதன@ ேபாC "றி உபேயாகிப வ :C 
வழக. 
 
ேத ேச" வாத ேநா$கான ம"க
: 
 நரசிம ேலகிய 
 பச லவண ெம/25 
 தாமிர ெம/ 
 வாைல ரச ெம/23 
 தி8 Nத ெம/2 
 அப	 ெம/ 
 அமி	த ந&தி ெம/ 
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CHEMICAL ASPECT 
CORROSIVE SUBLIMATE (PERCHLORIDE OF MERCURY) 
 A crystalline body, colorless, odorless, with an acrid persistent metallic taste; 
soluble in sixteen parts of cold water, in two parts of boiling water, and in three parts of 
alcohol 
 
General: 
Synonyms  : Hydrargyri chloridum corrosivum, corrosive mercuric chloride,  
   corrosive chloride of mercury, corrosive sublimate, bichloride of  
   mercury, Perchloride of mercury 
Molecular formula : HgCl2  
 
Physical characteristics: 
 Appearance   : white solid 
 Melting point   : 277º C 
 Boiling point   : 302º C 
 Color     : white.  
 Molar mass   : 271.52 g/mol  
 Density   : 5.43 g/cm3, solid.  
 Solubility in water  : 7.4 g/100ml (20º C) 
 Solubility in other solvents : 33 g/100ml (25º C) 
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Occurrence: 
 Prepared by the sublimation and condensation of a mixture of Manganese dioxide, 
Mercuric sulphate and Sodium chlorate. 
 Mercuric chloride is obtained by the action of chlorine on mercury or mercury (І) 
chloride, by the addition of hydro chloric acid to a hot, concentrated solution of mercury 
(І) compounds such as the nitrate 
 Heating a mixture of solid mercury (ІІ) sulphate and sodium chloride also affords 
volatile HgCl2, which sublimes and condenses in the form of small rhombic crystals. 
 
Medicinal use: 
 
 Syphilis was frequently treated with mercuric chloride before the advent of 
antibiotics. 
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CHEMICAL ASPECT 
CALOMEL (DIMERCURY DICHLORIDE) 
 The name calomel is thought to come from the Greek καλος beautiful, and µελας 
black. This name is probably due to its characteristic disproportionation reaction with 
ammonia, which gives a spectacular black coloration due to the finely dispersed metallic 
mercury formed. It is also referred to as the mineral horn quicksilver or horn mercury. 
This is a dense white or yellowish-white, odorless solid chemical compound. 
General: 
Synonyms  : Mercurous chloride; calomel, Calomelane, calomelite, Horn  
     mercury, Horn quick silver, Turpeth. 
Molecular formula : Hg2Cl2  
 
Physical characteristics: 
 Appearance   : white solid 
 Melting point   : 383º C 
 Color     : white.  
 Molar mass   : 472.09 g/mol  
 Density   : 7.150 g/cm3, solid.  
 Solubility in water  : 0.2 mg/100ml 
 Specific gravity  : 7.16 
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Occurrence: 
 A relatively rare mineral, associated with other mercury minerals, probably 
always secondary and late in the mineral sequence. It will be found in small brilliant 
crystals in cavities, associated with cinnabar and often perched on crystals of that 
mercury ore. Found in the U.S. at Terlingua, Texas, and near Murfreesboro, Arkansas; in 
Europe, at various cinnabar localities. 
 
Medicinal use: 
 
 It was once used medicinally as a  
  Purgative,  
  Cathartic,  
  Liver stimulant,  
  Insecticide and to eliminate parasitic worms 
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CHEMICAL ASPECT 
CINNABAR (MERCURY ІІ SULPHIDE) 
 Cinnabar, sometimes written cinnabarite, is a name applied to red mercury (II) 
sulfide (HgS), or native vermilion, the common ore of mercury. The name comes from 
the Greek - "kinnabari" - used by Theophrastus, and was probably applied to several 
distinct substances. Other sources say the word comes from the Persian zinjifrah, a word 
of uncertain origin. In Latin it was known as minium, meaning also "red lead" - a word 
probably borrowed from Iberian [2] (cf. Basque armineá "cinnabar"). Cinnabar is a 
colorful mineral that adds a unique color to the mineral color palette. Its cinnamon to 
scarlet red color can be very attractive.  
 
General: 
Synonyms  : mercury sulphide, mercury (II) sulphide, mercuric sulfide,  
   mercury sulfide, mercury (II) sulfide, chinese vermilion, mercury  
   monosulfide, monomercury sulfide, orange vermilion, red   
   cinnabar, red mercury sulphide, red mercuric sulfide, scarlet  
   vermilion, vermilion,  vermillion  
Molecular formula : HgS  
Physical characteristics: 
 Appearance : solid 
 Melting point : 584º C 
 Color   : bright scarlet or cinnamon red to a brick red.  
 Luster  : adamantine to submetallic in darker specimens.  
 Transparency : crystals are translucent to transparent.  
 Crystal System: trigonal; 32 
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Crystal habits:  
 Individual, well formed, large crystals are scarce; crusts and crystal complexes are 
more common; may be massive, or in capillary needles. Crystals that are found tend to be 
the six sided trigonal scalahedrons that appear to have opposing three sided pyramids. It 
also forms modified rhombohedrons, prismatic and twinned crystals as described above.  
 Cleavage  : perfect in three directions, forming prisms.  
 Fracture  : uneven to splintery.  
 Hardness  : 2 - 2.5.  
 Specific Gravity : 8.1+ (very heavy for a non-metallic mineral)  
 Streak   : red  
 Associated Minerals : realgar, pyrite, dolomite, quartz, stibnite and mercury 
 Other Characteristics : slightly sectile and crystals can be striated.  
 Best Field Indicators : crystal habit, density, cleavage, softness and color.  
 Stability  : Stable. 
 
Occurrence: 
 Generally cinnabar occurs as a vein-filling mineral associated with recent 
volcanic activity and alkaline hot springs. Cinnabar is found in all localities that yield 
mercury, notably Almadén (Spain); New Almaden (California); Hastings Mine and St. 
John's Mine, Vallejo, California; Idrija (Slovenia); New Idria (California); Landsberg, 
near Obermoschel in the Palatinate; Ripa, at the foot of the Apuan Alps (Tuscany); the 
mountain Avala (Serbia); Huancavelica (Peru); Terlingua (Texas); and the province of 
Guizhou in China, where fine crystals have been obtained. Cinnabar is still being 
deposited at the present day from the hot waters of Sulphur Bank, in California, and 
Steamboat Springs, Nevada. 
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Medicinal use: 
 
 Much fuss is made about medicinal use of Cinnabar, however Cinnabar has been 
used over the ages medicinally in the East and the West and its side effects are long 
known. 
 It is known to be highly toxic - perhaps the first record of this is in the 
Thoroughly Revised Materia Medica (1751) and later in the work Harm and Benefit in 
the Materia Medica (1893). 
 Cinnabar (contains mercury sulfide) has been used in Chinese traditional 
medicines for thousands of years as an ingredient in various remedies, and 40 cinnabar-
containing traditional medicines are still used today. 
 Pharmacological studies of cinnabar suggest sedative and hypnotic effects. 
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BOTANICAL ASPECT 
 
Zingiber officinale 
 
Classification: 
 Kingdom : plantae 
 Division : magnoliophyta 
 Class  : liliopsida 
 Order  : zingiberales 
 Family  : zingiberaceae 
 Genus  : Zingiber 
 Species : officinale 
 
Vernacular names:39 
 Tamil  : chukku 
 English : dried ginger 
 Hindi  : duk 
 Malayalam : chukka 
 Sanskrit : sunta 
 Telugu  : sonti 
 
Habitat: 38 
 Ginger is cultivated in many parts of india on a large scale in the warm, moist 
regions, chiefly in Madras, Cochin and Travancore and to a somewhat less extent in 
Bengal and Punjab. 
 
Habit: 
 Rhizome: Stout tuberous with erect leafy stems 0.6 – 1.2 m high, Leaves are 
narrow, sub sessile on the sheaths, linear lanceolate, 1.2 cm wide, glabrous 
 Flowers are greenish with a small dark purple or purplish black  
 Stamens are dark purple, as long as the lip, rather shorter than the corolla 
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Chemical constituents: 38 
 
 Essential oil contains sesquiterpene hydrocarbons, sesquiterpene alcohols, 
monoterpenoids. The predominant sesquiterpene hydrocarbon is Zingiberine.other 
sesquiterpenes are ar-curaemene, farnesene. The sesquiterpene alcohol is Zingiberol. The 
free amino acids present in ginger are glutamic acid, aspartic acid, serine, glycine, 
threonone, alanine, glutamine, γ-amino butyric acid, asparagines etc. gingerolis obtained 
from oleoresin. 
 
Action: 38 
 
 Aromatic, carminative, stimulant, stomachic, sialogogue, digestive, externally a 
local stimulant and rubefacient 
 
Uses: 38 
 
 Dry ginger is used as a carminative adjunct along with black pepper and long 
pepper under the name of trikatu. 
 Dry ginger is used as a corrective adjunct to purgatives to prevent nausea and 
vomiting. 
 Saubhagya sunti is used as a carminative tonic and in disorders of the alimentary 
canal in females after confinement. 
 In chronic rheumatism, infusion of chukku (1 in 24) taken warm just before going 
to bed, is often attended with best results. 
 In case of fainting etc; dry ginger rubbed to thin paste with water, is a nice anjan. 
 Powder of dried ginger mixed with ghee acts as carminative and appetizer. 
 In vaginismus powdered chukku well mixed with castor oil is applied to the 
painful parts. 
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Elettaria cardamomum 
 
Classification: 
 
 Kingdom : Plantae 
 Division : Magnoliophyta 
 Class  : Liliopsida 
 Order  : Zingiberales 
 Family  : Zingiberaceae 
 Genus  : Elettaria 
 Species : cardamomum 
 
Vernacular names: 39 
 
 Tam : Elam, ellakay, elakgai, elakaya 
 Eng : Cardamom, Malabar cardamom, lesser cardamom 
 Hind : Chhoti elachi 
 Guj : Elachi 
 Tel : Elakaya, pakkuln 
 Can : Elakki 
 Mah : Veldode, elachi 
 
Habitat: 
 
 Cultivated for its fruit in many parts of western and southern India, Ceylon and 
Burma 
 
Parts used: 
 
 Dried ripe seeds, oil from fruits 
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Chemical constituents: 38 
 
 Fixed oil, essential oil, the seeds contain a considerate amount of terpinyl acetate; 
cineole, free terpineol and probably also limonene are present. Potassium salts, starch, 
nitrogenous mucilage, yellow colouring matter, ligneous fibre and ash containing 
manganese. 
 
Action: 
 
 Aromatic, stimulant, carminative, stomachic and diuretic 
 
Uses: 38 
 
 Seeds which have a fragrant taste and aromatic odour, are generally used as a 
masticatory. They are valuable in many stomach complaints. Oil extracted from fruits is 
used in pharmacy and perfumery. 
 
 Cardamom can be safely used as a carminative in convalescence after diarrhoea. 
In the form of tincture or powder, cardamom are used both in eastern and western 
systems of medicine as a frequent adjunct to other stimulants, bitters and purgatives. 
 
 A decoction of cardamoms together with their pericarp and jaggery added is a 
popular home remedy to relieve giddiness caused by biliousness. A compound powder 
containing equal parts of cardamom seeds, ginger, cloves and caraway is a good 
stomachic in ½ drachm doses in atonic dyspepsia. 
 
 A powder made of equal parts of parched cardamom seeds, aniseeds and caraway 
seeds given in 1 teaspoonful doses is a good digestive. 
 
 A compound powder called elathi choornam is a good nutritive tonic and 
demulcent useful in bronchial affections, given in dose of 5- 20 grains three times a day. 
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BOTANICAL ASPECT 
 
Myrtus caryophyllus 
 
Classification: 
 Kingdom : plantae 
 Division : magnoliophyta 
 Class  : magnoliopsida 
 Order  : myrtales 
 Family  : myrtaceae 
 Genus  : Myrtus 
 Species : caryophyllus 
 
Synonyms: 40 
 Caryophyllus aromaticus 
 Eugenia caryophyllata 
 
Vernacular names: 39 
 Tamil  : Kirambu, Lavangam 
 English : Cloves 
 Sanskrit : Lavangha, Svisamgyam, devakusumum 
 Telugu  : Karavappu 
 French  : Gorifla 
Mah  : Lavang 
Hindi  : Laung, Long 
Arab  : Karang phul 
 
Habitat: 
 Ginger is cultivated in many parts of India. It is also cultivated in Ceylon. 
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Parts used: 
 Fruit, dried flower buds and oil 
 
Chemical constituents: 41 
 A heavy volatile oil, a camphor resin 
Caryophyllin or eugenin- a crystalline substance 
Tannin, woody fibre 
Gum eugenol, Acetyl eugenol 
Caryophyllene 
Furfural 
Methyl-amyl-ketone 
 
Action: 38 
 Aromatic, carminative, stimulant, stomachic, antispasmodic, external oil is 
antiseptic, local anaesthetic and rubefacient. 
 
Uses: 38 
 They are used to correct griping pain caused by purgatives to relieve flatulence, 
various forms of gastric irritability, colic, dyspepsia and to increase the flow of saliva. 
 A pill made of clove 4 parts, leaves of cannabis indices 4, long pepper 4, pellitory 
root 6 and honey 8 parts given in giddiness, dyspepsia and general debility. 
 A mixture of equal parts of cloves and chitretta has excellent effects in debility, 
loss of appetite and in convalescence after fever. 
 An infusion of senna to which are added cloves and ginger 3 grains each to the 
ounce of the infusion makes a good aromatic purgative. 
 A powder called lavangadhi choornam made of cloves, dry ginger, black pepper 
and fried borax taken in equal measure is useful in bronchitis. 
 A pill called devakusumadi rasa containing cloves, sandalwood paste, saffron and 
mercuric chloride is given in doses of 1 to 4 pills of one grain each three times a day in 
syphilitic affections as an alterative and tonic. This was recently tested in cases of 
secondary syphilis, in which the patients derived marked benefit from them. 
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MEL (HONEY) 
 
Vernacular names: 39 
 Tamil : Taen 
 Sans : Madhu, Makshika 
 Arab : Injubin, Asatulnahl 
 Pers : Shadab, Angebina 
 Punj : Saht 
 Kash : Mhach 
 Hind : Madha 
 Malay : Ayurmader 
Can : Jaentuppa 
 
Source: 38 
Bees hive or honey comb, where it is deposited by the honey bee. It occurs in the 
nectarines of flowers where from it is sucked by the bees and then stored up in the comb. 
The finest honey is the virgin honey which drains itself from the comb and that which is 
freshly collected from the hive. Honey sold in the bazaars is derived from the honey 
comb of several species of wild bees. 
 
Characters: 
 It is a viscid, saccharine substance, semi-translucent liquid of a light yellowish-
brown colour of an aromatic odour and of a sweet acrid taste. After a time it becomes 
opaque and crystalline. 
 
Constituents: 38 
 Grape sugar or dextrose, fruit sugar or levulose, wax, volatile oil, proteins, 
mucilage, colouring matter, formic acid and ash, ethereal oil, various phosphates, lime 
(calcium) and iron, most of the elements found in the human body are in small amounts 
present in honey. Honey contains both the fat soluble and water soluble vitamins. Honey 
contains a special protein secreted by the bee. 
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Varieties: 
 Eight types of honey are described by Susruta. 
 1. Makshika 2. Bhramara 3. Kshaudra 4. Pauttika 5. Chhatra 6. Argha  
7. Audalaka 8. Dala 
 
Action: 
 Demulcent, Laxative, Astringent, Detergent, Emollient 
 
Uses: 38 
 As a demulcent, honey and warm barley water are given internally in constipation 
and in indigestion, in bronchial affections, asthma, chronic cold, troublesome coughs and 
sore throat. It is a useful laxative for children. 
 A mixture of honey and distilled vinegar or lime juice in equal parts melted 
together by gentle heat is an excellent adjunct to cough mixtures. 
 In severe cases of malnutrition with heart weakness and in cases of pneumonia, 
honey has been found to have a marked effect in reviving the hearts action and keeping 
the patient alive. 
 In the west, honey is coming in to more and more extensive use in curing rickets, 
marasmus, malnutrition, scurvy and other conditions in which various malts, like cod-
liver oil and other patent foods were formerly prescribed. 
 A teaspoonful or two in a cupful of boiling water and taken while still warm is a 
refreshing and strengthening draught, giving much relief to those suffering from asthma. 
 The use of honey internally and of sunlight to the body direct, has been eulogized 
as an ideal remedy to regulate the secretion of the internal glands and calcium 
metabolism. 
 The ferment and a special protein as well as the vitamins in honey perhaps 
accounts for the beneficial action of honey in diabetes. 
 A paste of it with flour is a popular application to promote maturation of 
abscesses and ulcers. As an emollient it is used as a gargle to cure aphthae in the mouth 
and as a vehicle to other agents. 
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MATERIALS AND METHODS 
 
Preparation of the drug: 
To evaluate the efficacy of “Shanmuga Mezhugu” for “Azhal Keel Vayu” 
(Osteo Arthritis) has been selected as per siddha literature, Anupoga Vaithya 
Navaneetham by Abdullah sayabu.  
 
The Ingredients of Shanmuga Mezhugu are, 
 Veeram 
 Pooram 
 Lingam 
 Chukku 
 Elarisi 
 Kirambu 
 Thaen 
 
Collection of Drugs: 
 The raw drugs like veeram, pooram, lingam, chukku, elarisi, kirambu and thaen 
were collected from the indigenous drug shop, Chennai.  
 
METHOD OF PREPARATION: 
 
INGREDIENTS: 
 Veeram    - 105g 
 Pooram    - 105g 
 Lingam    - 105g 
 Chukku    - 315g 
 Elarisi     - 315g 
 Kirambu    - 315g 
 Thaen     - 1260g 
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Purification of the drugs: 
  
Purification of Lingam 
 
  Equal quantities of lemon juice, cow’s milk and Acalypha juice were mixed 
thoroughly. Lingam was kept in a mud vessel and heated. The above prepared juice was poured 
into the Lingam little by little until the entire juice finished off. 
 
Purification of Veeram: 
 
  Camphor was mixed with tendor coconut and put in a mud vessel. Veeram 
enclosed in a thin cloth was made hanging inside the vessel above the liquid level without 
touching it. Then the vessel heated for half an hour. 
 
Purification of Pooram: 
 
  Equal parts of betle leaves (Kammaru vetrilai) and pepper were made into a paste 
by grinding with some water. Then the paste was mixed with more water and poured into a mud 
vessel. Pooram enclosed in a thin cloth was made hanging inside the vessel and was kept 
immersed in the liquid level fully. Then the vessel was heated gently until the liquid inside the 
vessel reduced into one fourth of its original quantity. Then the Pooram taken out and washed in 
water, then kept in sun for drying. 
 
Purification of Chukku: 
 
  To purify Chukku the outer skin of it was peeled off by using a knife. 
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Preparation of the test drug: 
 
  Purified Veeram, Pooram and Lingam are taken 3 palam (105 grams) each and 
powdered separately. 
 Chukku, Kirambu and Elarisi are taken 9 palams (315 grams) each and powdered 
separately. 
 All these drugs were mixed together and grinded for 1 hour continuously. After all the 
drugs were thoroughly grinded, Honey in small quantities was added to the grinded drugs and 
kept on grinding for 6 hours (2 saamam) to make into mezhugu padham. Then the drug was 
collected in a ceramic vessel. 
 
Intended therapeutic use: 
 
 Shanmuga mezhugu in the dose of 130 mg b.d. with palm jaggery is given for 
Azhal Keel Vayu after meals. 
 
      VEERAM 
 
 BEFORE PURIFICATION     AFTER PURIFICATION 
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 BEFORE PURIFICATION     AFTER PURIFICATION 
 
    
 
 
      LINGAM 
 
 BEFORE PURIFICATION    AFTER PURIFICATION 
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BIOCHEMICAL ANALYSIS 
 
CHEMICAL ANALYSIS OF SHANMUGA MEZHUGU 
 
 
Sl. 
NO 
EXPERIMENT OBSERVATION INFERENCE 
1. Solubility: 
     a. A little of the sample is 
shaken well with distilled water 
      b. A little of the sample is 
shaken well with con HCl / con 
H2So4 
 
Sparingly soluble 
 
Insoluble in con HCl 
/ Con H2So4 
 
Insoluble 
2. Action Of Heat: 
     A small amount of the sample 
is taken in a dry test tube and 
heated gently at first and then 
strongly 
 
No white fumes 
evolved 
 
No brown fumes 
 
Absence of Carbonate 
 
Absence of Nitrate 
3. Flame Test: 
     A small amount of the sample 
is made in to a paste with con. HCl 
in a watch glass and introduced 
into non-luminous part of the 
Bunsen flame 
 
Red colour appear 
 
Presence of Calcium 
4. Ash Test: 
     A filter paper is soaked into a 
mixture of sample and add cobalt 
nitrate solution and introduced into 
the Bunsen flame and ignited 
 
No yellow colour 
flame 
 
Absence of sodium 
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PREPARATION OF EXTRACT: 
 5 gm of Shanmuga Mezhugu is weighed accurately and placed in a 250 ml clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 
minutes.  Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml 
with distilled water. This fluid was taken for analysis. 
SL.NO EXPERIMENT OBSERVATION INFERENCE 
I Test for Acid Radicals   
1.  
Test for Sulphate: 
 
a. 2 ml of the above prepared extract is 
taken in a test tube, to this, add 2ml of 
4% ammonium oxalate solution 
 
b. 2 ml of the above prepared extract is 
added with 2ml of dil. HCl is added 
until the effervescence ceases off. 
Then 2ml of Barium chloride solution 
is added 
 
 
 
No cloudy 
appearance 
 
 
 
Absence of sulphate. 
 
 
 
 
Absence of sulphate 
2. Test for Chloride: 
     2 ml of the above prepared extract is added 
with dil. HNO3 till the effervescence ceases.   
Then 2ml of silver nitrate solution is added 
 
No cloudy 
appearance 
 
Absence of chloride 
3. Test for Phosphate: 
     2 ml of the extract is treated with 2ml of 
ammonium molybdate solution and 2ml of 
Con. HNO3 
 
Cloudy yellow 
appearance present 
 
Presence of phosphate 
4. Test for Carbonate: 
    2 ml of the extract is treated with 2ml of 
magnesium sulphate solution 
 
No cloudy 
appearance 
 
Absence of Carbonate 
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5. Test for Nitrate: 
    1 gm of the substance is heated with copper 
turning and concentrated H2SO4 and viewed 
the test tube vertically down 
 
No characteristic 
changes 
 
Absence of Nitrate 
6. Test for Sulphide: 
     1 gm of the substance is treated with 2 ml 
of Con. HCl 
 
No rotten egg 
smelling gas evolved 
 
Absence of sulphide` 
7. Test for Fluoride & Oxalate: 
     2ml of extract is added with 2ml of dil 
acetic acid and 2ml of calcium chloride 
solution and heated 
 
No cloudy 
appearance 
 
Absence of fluoride 
and oxalate 
8. Test for Nitrite: 
     3 drops of the extract is placed on a filter 
paper, on that 2 drops of acetic acid and 2 
drops of benzidine solution is placed. 
 
No characteristic 
changes 
 
Absence of Nitrite 
9. Test for Borate: 
     2 pinches of the substance is made into paste 
by using sulphuric acid and alcohol (95%) and  
introduced into the blue flame 
 
No bluish green 
colour flame 
appeared 
 
Absence of Borate 
II Test For Basic Radicals   
1. Test for Lead 
     2 ml of the extract is added with 2ml of 
potassium iodide solution 
 
No yellow precipitate 
 
Absence of lead 
2. Test for Copper 
a. One pinch of substance is made in to 
paste with con. HCl in a watch glass 
and introduced into the non – 
luminous part of the Bunsen flame. 
b. 2 ml of extract is added with excess of 
ammonia solution 
 
Blue flame appeared 
 
 
 
Blue colour 
precipitate formed 
 
Presence of copper 
 
 
 
Presence of copper 
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3. Test for Aluminium: 
     To the 2ml of the extract sodium 
hydroxide is added in drops to excess 
 
No characteristic 
changes 
 
Absence of aluminium 
4. Test for Iron. 
a. To the 2ml of extract add 2 ml of 
ammonium thiocyanate solution. 
 
b. To the 2ml of extract add 2ml 
ammonium thiocynate solution and 
2ml of con HNo3 is added 
 
 
Mild red colour 
appeared 
 
Blood red colour 
appeared 
 
Presence of Iron 
 
 
Presence of Iron 
5. Test for Zinc 
          To 2ml of the extract sodium hydroxide 
solution is added in drops to excess      
 
White precipitate is 
formed 
 
Presence of Zinc 
6. Test for Calcium 
         2ml of the extract is added with 2ml of 
4% ammonium oxalate solution 
 
Cloudy appearance 
white precipitate is 
obtained 
 
Presence of Calcium 
7. Test for Magnesium 
     To 2ml of extract sodium hydroxide 
solution is added in drops to excess 
 
White precipitate is 
obtained 
 
Presence of Magnesium 
8 Test for Ammonium: 
     To 2ml of extract few ml of Nessler’s 
reagent and excess of sodium hydroxide 
solution are added 
 
No brown colour 
appeared 
 
Absence of ammonium 
9. Test for Potassium: 
    A pinch of substance is treated with 2ml of 
sodium nitrate solution and then treated with 
2ml of cobalt nitrate in 30% glacial acetic 
acid 
 
 
No yellowish 
precipitate is obtained 
 
Absence of Potassium 
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10. Test for Sodium 
     2 Pinches of the substance is made into 
paste by using HCl and introduced in to the 
blue flame, of Bunsen burner 
 
No yellow colour 
flame  appeared 
 
Absence of Sodium 
11. Test for Mercury 
     2 ml of the extract is treated with 2ml of 
sodium hydroxide solution 
 
Yellow precipitate is 
obtained 
 
Presence of Mercury 
12. Test for Arsenic: 
     2ml of extract is treated with 2ml of silver 
nitrate solution 
 
No brownish red 
precipitate is obtained 
 
Absence of Arsenic 
  III.          Miscellaneous:   
1. Test for Starch: 
     2 ml of extract is treated with weak Iodine 
solution 
 
No blue colour 
developed 
 
Absence of starch 
2. Test for Reducing Sugar: 
    5 ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 2 
minutes and added 8 to 10 drops of the extract 
and again boil it for 2 minutes. The colour 
changes are noted 
 
Brick red colour 
developed 
 
Presence of Reducing 
sugar 
3. Test for the Alkaloids: 
a. 2ml of the extract is treated with 2ml 
of potassium iodide solution. 
b. 2ml of extract is treated with 2ml of 
picric acid. 
c. 2ml of the extract is treated with 2ml 
of phospho tungstic acid 
 
 
No red colour 
develops 
No yellow colour 
developed 
No white precipitate 
obtained 
 
 
 
Absence of alkaloid 
 
4. Test for Tannic Acid: 
    2 ml of extract is treated with 2ml of ferric 
chloride solution 
 
No black precipitate 
appeared 
 
Absence of Tannic acid 
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5. Test for Unsaturated 
Compound: 
    To the 2ml of extract 2ml of potassium 
permanganate solution is added 
 
 
Potassium 
Permanganate is not 
decolourized 
 
 
Absence of unsaturated 
compound 
6. Test for Amino Acid: 
      2 drops of the extract is placed on filter 
paper and dried well 
 
No violet colour 
developed 
 
Absence of amino acids 
7. Test for type of Compound 
2 ml of the extract is treated with 2 ml of 
ferric chloride solution 
 
No green colour 
developed 
 
No red colour 
developed 
 
No violet colour 
developed 
 
No blue colour 
developed 
 
Absence of oxy quinole 
epineplhrine and phro 
catechol 
Anti pyrine, Aliphatic 
amino acids and 
meconic acid are absent 
Apomorphine salicylate 
and resorcinol are 
absent 
Morphine, phenol 
cresol and hydro 
quinine are absent 
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QUANTITATIVE ANALYSIS 
 
 
 The quantitative analysis of the drug Shanmuga Mezhugu was done in Mettex 
laboratories of India, Chennai – 32. 
 
Quantitative analysis: 
 
Aim: 
 
 To determine the metals and minerals in Shanmuga Mezhugu. 
 
Instrument: 
 
 Atomic Absorption Spectrometer (AAS) with air – acetylene. 
 
Apparatus and equipment: 
 
 500 ml glass beakers, hot plate, watch glass, 100 ml standard flask. 
 
Chemicals: 
 
 Nitric acid, hydrochloric acid, certified reference standards. 
 
Sample preparation: 
 
 Transfer a weighed Shanmuga Mezhugu in to a 500 ml beaker. Add 10 ml of 1 + 
1 HNO3 and 10 ml of 1 + 1 HCl and heat on a hot plate until the sample gets dissolved. 
Cool and filter to remove insoluble material. Transfer sample to 100 ml volumetric flask, 
adjust volume to 100 ml and mix. Take all precautions to avoid contamination at all 
stages. Prepare a reagent blank containing same amounts of acids used in the preparation 
of sample. Aspirate the standards and sample in to AAS instrument as per instrument 
procedure. 
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Calculation: 
 Percentage of the element = A/B × 100 
  A: concentration of sample in ppm. 
  B: Dilution factor. 42 
 
Physical properties: 
 
Loss on drying: 
 
 Five grams of Shanmuga Mezhugu is heated in a hot oven at 40ºC to constant 
weight. The percentage of loss of weight was calculated. 
 
Determination of ash value: 
 
 Weigh accurately 2 – 3 grams of Shanmuga Mezhugu in tarred platinum or silica 
dish and incinerate at a temperature not exceeding 450ºC until free from carbon, cool and 
weigh. Calculate the percentage of ash with free reference to the air dried drug. 
 
Acid insoluble ash: 
 
 Boil the ash for 5 minutes with 25 ml of 1 : 1 dilute HCl. Collect the insoluble 
matter in Gooch – crucible on an ash less filter paper, wash with hot water and ignite, 
cool in a dessicator and weigh. Calculate the percentage of acid insoluble ash with 
reference to the air dried drug. 
 
Water soluble ash: 
 
 To the Gooch crucible containing the total ash, add 25 ml of water and boil for 5 
minutes. Collect the insoluble matter in a sintered glass crucible or on ash less filter 
paper. Wash with hot water and ignite in a crucible for 15 minutes at a temperature not 
exceeding 450ºC. Subtract the weight of the insoluble matter from the weight of the ash. 
The difference of weight represents the water soluble ash. Calculate the percentage of 
water soluble ash with reference to the air dried drug. 
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Alkalinity of water soluble ash: 
 
 Five grams of Shanmuga Mezhugu converted to ash, boiled with water, filtered. 
Filtrate was titrated against 0.1N of HCl using phenolphthalein as an indicator. 
 
 Alkalinity of water soluble ash = X × St of acid / 0.1 × W 
 
 X = Titre value. 
 
 W = Weight of the material taken. 
 
 Alkalinity is given as ml of 0.1N of HCl equated to 1 gm. 
 
pH: 
 
 Five grams of Shanmuga Mezhugu is weighed accurately and placed in clear 100 
ml beaker. Then 50 ml of distilled water is added to it and dissolved well. Wait for 30 
minutes and then apply in to pH meter at standard buffer solution of 4.0, 7.0 and 9.2. 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACOLOGICAL 
STUDY 
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STUDIES ON ANTI-INFLAMMATORY, ANALGESIC AND ANTIPYRETIC 
PROPERTIES OF SHANMUGA MEZHUGU IN EXPERIMENTAL ANIMAL 
MODELS 
 
Introduction: 
 Inflammation or phlogesis is a pathophysiological response of living tissue to 
injuries that leads to the local accumulation of plasmatic fluid and blood cells. Although 
it is a defense mechanism, the complex events and mediators involved in the 
inflammatory reaction can induce, maintain or aggravate many diseases. However, 
studies have been continuing on inflammatory diseases and the side effects of the 
currently available anti-inflammatory drugs pose a major problem during their clinical 
use. Therefore, development of newer and more powerful anti-inflammatory drugs with 
lesser side effects is necessary. Keeping this in view, the present study has been 
undertaken to investigate the anti-inflammatory, analgesic, and antipyretic potential of 
Shanmuga Mezhugu in experimental animal models. 
 
Materials and methods: 
Animals: 
 Albino mice of both sex weighing between (18-22 g) and Albino Wistar rats of 
the either sex (180-200 g) were used for the present study. They were maintained under 
standard environmental conditions and were fed with standard pellet diet and water ad 
libitum.  
 
Chemicals and drugs used: 
 Shanmuga Mezhugu was dissolved in 10% propylene glycol (200mg/ml) prior to 
administration. In the present study Indomethacin, Aspirin and paracetamol were used as 
the standard drugs.  
Acute toxicity study: 
 For toxicity studies the test compounds in the range of doses 100-4000 mg/kg 
were administered in five groups of 6 mice respectively. The mortality rates were 
observed after 48 hours.  
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Anti-inflammatory model: 
 
Formalin-induced paw oedema in rats: 
 The rats were divided into 3 groups (n = 6). The test group animals were treated 
with Shanmuga Mezhugu (400 mg/kg , p.o.), Indomethacin (10 mg/kg , p.o.) and control 
vehicle per oral for remaining two groups and the paw volume was measured at 0 h and 2 
h after formalin injection using a plethysmometer. The animals were pretreated with the 
Shanmuga Mezhugu 1 h before the administration of formalin. Acute inflammation was 
produced by the subplanter administration of 0.1 ml of (1%, w/v) formalin in the right 
paw of the rats. The ratio of the anti-inflammatory effect of Shanmuga Mezhugu was 
calculated by the following equation:  
 
  Anti-inflammatory activity (%) = (1 - D / C) x 100 
 
 Where D represents the percentage difference in paw volume after Shanmuga 
Mezhugu was administered to the rats, and C represents the percentage difference of 
volume in the control groups. 
 
Analgesic activity: 
 Shanmuga Mezhugu at the dose of 400 mg/kg and the standard drug Aspirin 100 
mg/kg (Acetic acid induced writhing response in mice) and Pentazocin 5 mg/kg (Hot 
plate reaction time in mice) were administered to three groups of six mice in each 
paradigm.  
 
Acetic acid-induced writhing test: 
  Acetic acid solution (15 mg/ml) at the dose of 400mg/kg body weight was 
injected (i.p.) and the number of writhes during the following 20 min period was 
observed. A significant reduction in the number of writhes by drug treatment as 
compared to vehicle treated animals was considered as a positive analgesic response. The 
percentage inhibition of writhing was then calculated. Aspirin (100 mg/kg, i.p.) was used 
as standard.  
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Hot plate reaction time in mice: 
 Mice were screened by placing them on a hot plate maintained at 55 ± 1°C and 
the reaction time in seconds for hind paw licking or jumping were recorded. Only mice 
which reacted within 15 sec and which did not show large variation when tested on four 
separated occasions, each 15 min apart, were used in this study. Pentazocin (5 mg/kg, 
i.p.) was used as standard. The time for hind paw licking or jumping on the heated plate 
of analgesiometer was taken as the reaction time.  
 
Antipyretic evaluation by yeast-induced pyrexia method: 
 Rats were divided into three groups of six rats in each and were trained to remain 
quiet in a restraint cage. A thermister probe was inserted 3-4 cm deep into the rectum and 
fastened to the tail by an adhesive tape and the temperature was measured on a 
thermometer. The normal body temperature of each rat was measured rectally at 
predetermined intervals and recorded. Fever was induced by a subcutaneous injection of 
20ml/kg body wt. of 20% w/v yeast suspended in methyl cellulose solution. Rats were 
then returned to their housing cage. After 24 h of yeast injection, the animals were again 
restrained in individual cages for the recording of their rectal temperatures as described 
previously. Shanmuga Mezhugu 400mg/kg body wt was administered orally to a group of 
animals. 10% Propylene glycol (5ml/kg, body wt.) was administered orally to the control 
group of animals. The third group of animals received the standard drug paracetamol 
(150 mg/kg, body wt.) orally. Rats were restrained for recording of their rectal 
temperatures at intervals of one hour, after the drug administration.  
 
Statistical analysis: 
 The experimental results were expressed as the mean ± S.E.M. Data were 
assessed by the method of analysis of ANOVA followed by student's t-test. P value of < 
0.05 was considered as statistically significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL STUDY 
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கீ வா 
 
ேவெபயக	: 
 
 சவலி, 	வலி, ேமகைல, டவா, ஆமவாத15 
 
இய: 
 
 இ, கீகள வளற  ! ேநாைய உ%டாவதா 
கீவாெவன(, 	கள ேநாைய உ%டாவதா 	வலி 
எ*+, இேநா, ெப.பா/ ேமக0தி* ெதாட12 ேநாயாக வ.வதா 
ேமகைல எ*+, 3	கைள டகி ைவ4பதா டவா எ*+, 
வய5றி மத உ%டாகி ஐய0ைத4 ெப.கி இேநா, உ%டாவதா 
ஆமவாத என( ெபய1 ெபற. 
 
 கீகள வ 78வ, 0வ, ேநாவ தலியவைற உ%டாகி 
மடக(, ந7ட(, அைசக( ஒடாம ெச,, ப	ைகய5 இ.0தி, 
ஐய  ! ;ர தலிய ைண ேநா,கைள உ%டா 
இய2ைடய. 15 
 
  “வள ைம த*னைல ெக	 
  வலிட* வ 7க ;ர கா, 
  	க ேடா+ 	கிேய ெநா 
  	க ட*ன* ந7. ;ர 
  தா8ெகாணா வலிட* ெநாதி	 மேம.” 
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எ: 
 
 வளகீ வா,  
 அழகீ வா,  
 ஐயகீ வா,  
 வளஅழகீ வா,   
 வளஐயகீ வா,  
 அழவளகீ வா,  
 அழஐயகீ வா,   
 ஐயவளகீ வா,  
 ஐயஅழகீ வா,  
 றகீ வா 
 
ேநா வ வழி: 
 
 வளற0ைத0 ?%	 உண(களாகிய வாைழகா,, 
உ.ைளகிழ8, தலிய ெபா.@கைள, ெசயகைள, ள1Aசித. 
ெபா.@கைள உ%பதா/, ள1 காறிலB	பட, மைழய5 நைனத, 
பன வாைடய5 ப	0தி.0த, உய1த மைலய5 த8த ஆகிய 
ஐயற0ைத0 ?%	 வைககளா/ இேநா, ப5ற. அ*றி, 
ெப% டா ப5றத ேமக ேநா,0 ைணயாக(, தா, தைதயC* 
வழியாக( வ.வ%	. 
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அழ கீ வா: 
 
  “ப50தகீ வா,( த*னா 
  ப5ற8கீ* 	 வ 78கிA 
  சி0த1ெச, ம.0 வ0D 
  சீ1படா0 த*ைம0 தாகி0 
  த0த+ கா,Aசக%	 
  சாலேவ தைனதா* தேத 
  ெம0த+ சிகிAைச த*னா 
  ெம*ேம ந78 ம4பா”. 13 
ெபா	: 
 
 வளற த*னைலய5 மி@ள ேபா, அழ ற0ைத0 
?%ட !ய உண(, ெசய தலியவறா ப5ற ேநாயா. 
இேநாய5, !கள உ%டா வ 7க நாEநா@ ெப.0 
ெகா%ேட வ, மித அழ ற0தா கீகள* இைடேய உ@ள பைச 
வற%	 பைசய+ கீ அைச ேபாெதலா நைடைடத/, 
“க/” “க/” ெக*ற ஓ1 ஒலி உ%டாவமா, இ.. சில 
ேவைளகள, கீ/ கீ  ! ஒ!ெகா%	, ஒ. கழி ேபால மடக 
!யாமேல நி*+ வ5	வ உ%	. இேநா, சி+;ர வ.. 
 
நாநைட: 
 “தி.0தமா வாத0 ேதாேட த78ெகா	 ப50தD ேசC 
 ெபா.க@ ேதா+ ெநா ேபாதேவ ப5!” 14 
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MODERN CONCEPT 
 
OSTEO ARTHRITIS 
 
 Osteo Arthritis is a degenerative joint disease without systemic manifestations. It 
is characterized by degeneration of cartilage and hypertrophy of bone at the articular 
margins. 
 
Classification: 
 
 1. Primary   – Idiopathic, Generalized OA, Erosive OA 
 2. Secondary to  – a. congenital developmental defects, Dysplasia,   
        Malalignment, Osteochondritis. 
      b. Trauma 
      c. Prior inflammation 
      d. Metabolic arthropathies (Wilson’s disease, Haemo  
        chromatosis, Ochronosis) 
      e. Acromegaly, Obesity 
      f. Haemarthrosis, Osteonecrosis 
 
Clinical features: 
 Age   – usually elderly 
 Joint distribution  – mono or oligo arthritis 
 Most frequent site  – knee, hips, lumbar and cervical spine, distal and proximal 
       inter phalangeal joint, first carpo metacarpal joint 
 Joint usually spared  – metacarpo phalangeal joint, wrist, elbow, ankles 
 Systemic manifestation – absent 
 Morning stiffness  – absent or less than 30 minutes 
 Joint exam   – local tenderness, bony / soft tissue swelling, crepitus 
 Synovial fluid  – normal viscosity and mucin 
       Leukocytes <2000/cumm, usually mono nuclear cells 
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Biochemical changes in OA cartilage: 
 
- increased water 
- decreased collagen, proteoglycan and keratin sulphate 
- increased chondroitin 4:6 ratio 
- increased collagenase and proteoglycanase 
 
Pathological features of OA: 
 
 Bone    – subchondral sclerosis, cortical buttressing, trabecular  
       hypertrophy, osteophyte, cyst, structural collapse 
 Cartilage   – fibrillation, cratering, cartilage proliferation 
 Synovial membrane  – fibrosis, patchy inflammation 
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CLINICAL STUDY 
 
Selection of patients: 
 
30 patients of both sexes were selected from the outpatient and inpatient 
departments of National Institute of Siddha. Chennai – 47 by present inclusion, exclusion 
and withdrawal criteria. 
 
Criteria for selection: 
 
Inclusion criteria: 
 
 The patients selected for clinical trial had the following criteria. 
 - Age above 35 years 
 - Wiling to attend the OPD once in 5 days for 48 days 
 - Pain 
 - Swelling – measurement of the knee joint is noted 
 - Stiffness 
 - Limitation of movements 
 - Joint tenderness 
 - Crepitation of the joints 
 
 Radiological investigations help in diagnosis of, 
  1. Narrowing of joint space 
  2. Osteophytes 
  3. Subchondral sclerosis 
  4. Subchondral cyst 
 
 The signs and symptoms vary in its severity from patient to patient. 
 
 
 
 111 
Exclusion criteria: 
 
1. Rheumatoid arthritis, 
2. Tubercular arthritis, 
3. Syphilitic arthritis, 
4. Gout, 
5. Haemorrhagic effusion. 
6. Malignancy 
 
Withdrawal criteria: 
1. Severe pain 
2. Any other acute illness. 
 
 The drug “Shanmuga Mezhugu” was administered internally in a dose of 130 mg 
b.d. with palm jaggery after food for 25 days over a period of 50 days i.e. five days drug 
treatment and the next five days no treatment in a span of 10 days.. 
 
Diet Restrictions and Medical advice: 
 
-  The patients were advised to take easily digestable and highly nutritive foods 
-  they were advised to avoid food like potato, green plantain, curd, dhal, Bitter                               
 Guard, Sesban, Tamarind etc. 
- Advised to avoid cold damp climate. 
- Obese patients were advised to reduce their weight in order to avoid stress 
- To avoid stress, walking is reduced; if they walk they are advised to the stick for                                                                        
  support 
Exercise for strengthening muscles around the knee joint: 
 
 Simple exercise that promote flexibility and strengthen the muscles around the 
knee joint can go along way towards warding off problems. In many cases, these 
exercises can also help hasten recovery after a knee injury. Weak or tight muscles are an 
important cause of knee injuries. 
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 Hence, it is advisable to make the time and effort to strengthen the muscle around 
the knee. However, if one is already suffering from pain in the knee, these exercises 
should be performed after consulting a doctor. To derive maximum benefit from the 
following exercises, they should be performed once or twice a day, repeating every 
exercise five to ten times for each knee. 
 
Thigh firmer: 
 Sit on the edge of a chair with one leg stretched out in front and the heel resting 
on the floor; tighten the muscle that runs across in front of the knee by flexing the toes 
back. Simultaneously, push the back of the knee towards the floor and feel the stretch 
there as well as at the back of the ankle. Hold for 5 seconds. Repeat the same with the 
other leg. 
 
Knee flexion and extension: 
 Sit straight on a chair and bend the knee by pulling the knee under the chair. Rest 
the foot on the toes. Hold for 5 seconds. Keep the foot relaxed and slowly raise it up to 
straighten the knee. Hold for 5 seconds and then slowly lower the foot to the floor. 
Repeat the same with the other leg. 
 
Straight leg lift: 
 Lie flat on the back with the stomach pulled in, the knee of one leg bent and the 
foot flat on the floor. Extend the other leg and lift it slowly as far as is comfortably 
possible, without bending the knee. Hold for 5 seconds and slowly lower the leg. Repeat 
the same with the other leg. 
 
STASTISTICAL ANALYSIS 
  
The reduction in the proportion of patients with signs and symptoms after 
treatment was analyzed using paired t-test 
 Chi-square test was used to study the significant between before and after 
treatment on severity of pain. 
KNEE XRAY – NORMAL 
 
    
 
 
KNEE XRAY – OSTEO ARTHRITIS 
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RESULTS ANS OBSERVATIONS 
 
Results of biochemical analysis of Shanmuga mezhugu 
 
Table 1 
 
Physical properties: 
 
 
S.No 
 
Parameters 
 
Results 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
 
 
Loss of drying at105ºC, (%) 
 
Ash value at 550ºC, (%) 
 
Water soluble, (%) 
 
Alkalinity as CaCO3 in water soluble ash, (%) 
 
Acid insoluble ash, (%) 
 
pH at 10% aqueous solution 
 
 
0.21 
 
1.85 
 
44.17 
 
0.02 
 
0.35 
 
3.85 
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Table 2 
Qualitative analysis: 
 
 
S.No 
 
Parameters 
 
 
Results 
 
1. 
2. 
 
Calcium 
 
Phosphate 
 
Present 
 
Present 
 
 
Table 3 
Quantitative analysis: 
 
 
S.No 
 
 
Parameters 
 
 
Results 
 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
 
Manganese 
 
Magnesium 
 
Zinc 
 
Copper 
 
Iron 
 
Calcium 
 
123 mg/kg 
 
707 mg/kg 
 
30.2 mg/kg 
 
15.3 mg/kg 
 
357 mg/kg 
 
0.23 % 
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RESULTS AND OBSERVATIONS 
Test for acute toxicity: 
 The drug Shanmuga Mezhugu found to be non-toxic up to dose 4g/kg body 
weight. Shanmuga Mezhugu did not cause any death of the animals tested. Hence one 
tenth of the maximum dose was used as therapeutic dose in these studies. 
 
Table-1:  Incremental dose finding experiment and its Signs of Toxicity of 
Shanmuga Mezhugu 
No Treatment 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. I 50 + - - - - + - - - - - - - - - - - - - - 
2. II 100 + - - - - + - - - - - - - - - - - - - - 
3. III 250 + - - - - + - - - - - - + - - - - - - - 
4. IV 500 + - - - - + - - - - - - - - - - - - - - 
5. V 1000 + - - - + + - - - - - - - - - - - - - - 
6. VI 2000 + - - + + + - - - - - - - + - - - - - - 
7. VII 4000 + - - + + + - - - - - + - - - - - - + - 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Increased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. 
Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Number of Deaths 
(Mortality) 
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ANTI-INFLAMMATORY STUDIES  
The anti-inflammatory potential of Shanmuga Mezhugu (400 mg/kg) against various 
experimental animal models exhibited significant (P<0.05) anti-inflammatory activity. 
The effects of Shanmuga Mezhugu and Indomethacin on the inflammation induced by 
formalin are summarized in Table-1.  
 
Table-1. Effect of Shanmuga Mezhugu on formalin induced paw oedema 
S.no Treatment Dose(mg/kg) mean increase in     
paw volume(ml) 
percentage inhibition 
1 Control 5ml/kg 0.78±.0.039 - 
2 Indomethacin (IM) 10mg/kg 0.31±0.017** 60.25 
3 Shanmuga Mezhugu 
(SM) 
400mg/kg 0.34.8±0.022** 55.38 
Values were compared with control 
P<0.01 was considered as significant 
 
 
0.78
0.31 0.34
0
0.2
0.4
0.6
0.8
control IM SM
RESULTS OF ANTIINFLAMMATORY ACTIVITY OF SHANMUGA 
MEZHUGU
mean increase in paw volume
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ACETIC ACID-INDUCED WRITHING IN MICE  
 The results of the acetic acid induced writhing in mice showed that, the drug 
Shanmuga Mezhugu at the doses of 400 mg/kg exhibited significant (P < 0.01) inhibition 
of the writhes at the rate of 49.89% when compared to that of control. Thus showing its 
peripheral analgesic activity. 
Table 2. Effects of Shanmuga Mezhugu and aspirin on writhing induced by acetic acid in 
mice.  
Treatment  Dose (mg/kg)  Number of writhes (per 20 min)  Inhibition (%)  
Control  -  38.24±2.33  -  
SM  400  19.16±1.81  49.89  
Aspirin  100  13.00±1.27 
b
 
66.0  
 
The results given are mean±S.E.M.; number of animal used (n=6)  
b 
P < 0.01 Experimental groups were compared with control  
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HOTPLATE REACTION TIME IN MICE 
  
Table 3. Effects of Shanmuga Mezhugu and pentazocin on hot plate 
reaction time in mice.  
Treatment  Dose (mg/kg)            Mean latent time   
 Initial                       After 30 min  
Control  -  7.85±0.79  7.62±0.51  
SM  400  8.36±0.67  16.43±1.11  
Pentazocin  5  7.13±0.78 b 12.19±1.49  
 
The results given are mean±S.E.M.; number of animal used (n=6)  
b 
P < 0.01 Experimental groups were compared with control  
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YEAST-INDUCED HYPERPYREXIA 
 The antipyretic effect started from the first hour and was maintained for 2 h, after 
administration of the Shanmuga Mezhugu. The result obtained from both the standard and 
Shanmuga Mezhugu treated rats were compared with the control group and a significant 
reduction in the yeast induced elevated rectal temperature by Shanmuga Mezhugu 
(P<0.01) was observed (Table 3). 
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Table 4. The effect of Shanmuga Mezhugu and paracetamol on yeast-induced pyrexia in rats.  
    Rectal temperature (°C)  
After yeast injection at After drug administration  Treatment  
0 h  24 h  1 h  2 h  3 h  4 h  
Vehicle5ml/kg  37.6±0.03  39.8±0.03  39.6±0.03  39.7±0.04  39.9±0.05  39.9±0.04 
Paracetamol 
150mg/kg  
38±0.03
b
 
39.9±0.03  38.8±0.04  38.5±0.03b 37.7±0.04b 37.6±0.03  
SM 400mg/kg  39.9±0.05  39.6±0.04  39.7±0.03b 38.4±0.03b 37.7±0.05  37.6±0.04b 
 
The results given are mean±S.E.M.; number of animal used (n=6)  
b 
P < 0.01 Experimental groups were compared with control  
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RESULTS OF CLINICAL ASSESSMENT: 
  
 For the clinical study of SHANMUGA MEZHUGU in Azhal Keel Vayu, 30 
Patients were selected. 
 
GENDER DISTRIBUTION: 
 
S.NO AGE IN YEAR NO. OF MALE PATIENTS NO. OF FEMALE PATIENTS 
1. 30-40 1 3 
2. 41-50 1 7 
3. 51-60 4 7 
4. 61-70 4 3 
 TOTAL 10 20 
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AGE WISE DISTRIBUTION: 
 
 
 
 
 
 
 
 
 
AGE WISE DISTRIBUTION
4
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 According to age wise distribution 13.33% were in 30-40 years, 26.66% were in 
41-50 years, 36.66% were in 51-60 years, 23.33% were in 61-70 years. 
 
 
 
S.NO AGE IN YEAR NO. OF PATIENTS PERCENTAGE 
1. 30-40 4 13.33 
2. 41-50 8 26.66 
3. 51-60 11 36.66 
4. 61-70 7 23.33 
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RESPONSE IN PERCENTAGE: 
 
 
 In the clinical trial done for 30 patients, good response is obtained for 80%, 
obtained optimum fair response is 20%, and poor response is 10% of cases. 
 
 
RESPONSE
FAIR, 3, 10%
POOR, 3, 10%
GOOD. 24. 80%
 
S.NO Response No. of patients Percentage 
1. Good 24 80 
2. Fair 3 10 
3. Poor 3 10 
 Total 30 100 
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movement 
 
 
Measurement 
(in cm) 
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S. 
NO 
 
 
OP.NO 
 
 
NAME 
 
 
A/S 
 
OP                         
/ 
IP 
 
Right
    / 
  left BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
Right ++ - + - ΙΙ - 38 37.5 + - + + + - 1. AG3925 Violet 41/F OP 
Left - - - - - - 37 37 - - - - - - 
Right ++ + + - ΙΙ Ι 38 37 + - + + + - 2. AG3985 Narayanan 53/M OP 
Left + - + - Ι - 37 36 + - + + + - 
Right - - - - - - 32 32 - - - - - - 3. AG4085 Subbulakshmi 52/F OP 
Left ++ + + - ΙΙ - 33 32 + - + + + - 
Right ++ + + - ΙΙ - 32 31.5 + - - - + - 4. AG4206 Jaya 45/F OP 
Left ++ - + - ΙΙ - 31 30.5 + - - - + - 
Right ++ - + - ΙΙ - 38 37 + - + + + - 5. AG4320 Rajamani 52/F OP 
Left ++ - + - ΙΙ - 38 37 + - + + + - 
Right ++ - + - ΙΙ - 35 34 + - - + + - 6. AG4326 Gnaneswari 38/F OP 
Left +++ + ++ - ΙΙ Ι 36 34.5 + - + + + - 
Right ++ - + - ΙΙ - 38 37 + - + - + - 7. AG4375 Padma 58/F OP 
Left ++ - + - ΙΙ Ι 38 37 + - + - + - 
Right ++ + + + ΙΙ Ι 26 26 + + + + + + 8. AG4378 Jayaraman 62/M OP 
Left ++ + + + ΙΙ Ι 26 26 + + + + + + 
Right ++ - + - ΙΙ - 35 34 + - + + + - 9. AG4785 Malligeswari 53/F OP 
Left ++ + + - ΙΙ - 35.5 35 + - + + + - 
Right + - + - Ι - 37 36 + - + + + - 10. AG4807 Gomathi 42/F OP 
Left ++ + + - ΙΙ - 38 37 + - + + + - 
Right ++ + + - ΙΙ - 38.5 37.5 + + - - + - 11. AG4892 Mala 38/F OP 
Left ++ - + - Ι - 37 36.5 + - - - + - 
Right + - + - Ι Ι 41 40 + - + + - - 12 AG4916 Jegannathan 68/M OP 
Left ++ + + + ΙΙ Ι 42 41 + + + + - - 
Right ++ + + - ΙΙ Ι 42 41.5 + - + + + - 11   13. AG4943 Chandran 46/M OP 
Left ++ - + - ΙΙ - 41 41 + - + + + - 
Right ++ + ++ + ΙΙ - 44 43 + - + + + - 14. AG5035 Rukmani 50/F OP 
Left ++ - + - ΙΙ - 44 43 + - + + + - 
Right ++ - ++ - ΙΙ - 30.5 30 ++ - + + - - 15 AG5320 Ummakulzhan 36/F OP 
Left ++ - + - ΙΙ Ι 30.5 30 ++ + + + - - 
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Measurement 
(in cm) 
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Crepitation on 
movements 
 
Swelling 
 
 
S. 
NO 
 
 
OP.NO 
 
 
NAME 
 
 
A/S 
 
OP 
/ 
IP 
 
Right 
    / 
  left BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
Right ++ + ++ + ΙΙ Ι 38 37 + - + + + - 16 AG6616 Lalitha 66/F OP 
OP Left ++ - + - Ι  38 37 + - + + + - 
Right - - - - - - 36.5 36.5 - - - - - - 17 AG6634 Charlet 49/F OP 
Left ++ - + - ΙΙ - 38 37 + - + + + - 
Right ++ - ++ + ΙΙ - 36.5 35.5 + - - - + - 18 AG6993 Baby 59/F OP 
Left + - + - ΙΙ Ι 36 36 + - - - + - 
Right ++ - + - ΙΙ - 32.5 32 + - + + + - 19 AG7779 Anbu 51/M OP 
Left - - - - - - 32 32 - - - - - - 
Right ++ + + - ΙΙ Ι 32 30 + - + + + - 20 AG7802 Ayyappan 58/M OP 
Left + - + - ΙΙ - 30 29.5 + - + + + - 
Right ++ - + - ΙΙ - 32 31 + - + + + - 21 AG7860 Pachaiyappan 54/M OP 
Left ++ - + - ΙΙ - 32.5 31.5 + - + + + - 
Right ++ - + - ΙΙ - 40 39.5 + - + + - - 22 702 Rukmani 55/F IP 
Left - - - - - - 39 39 - - - - - - 
Right ++ - + - Ι - 39 38.5 + - + + - - 23 722 Maniyammal 48/F IP 
Left - - - - - - 38 38 - - - - - - 
Right ++ + + + ΙΙ Ι 37 37 + + + + + + 24 741 Ariyamala 69/F IP 
Left + + + + Ι Ι 36.5 36.5 + + + + + + 
Right ++ - ++ - ΙΙ Ι 39 38 + - + + + - 25 749 Vedanayagam 51/F IP 
Left ++ - + - ΙΙ Ι 39 38 + - + + + - 
Right ++ + ++ + ΙΙ - 33.5 32.5 + - - - + - 26 748 Mohana 64/F IP 
Left +++ ++ ++ + ΙΙ Ι 34.5 33.5 + + - - + + 
Right - - - - - - 34 34 - - - - - - 27 754 Andal 45/F IP 
Left ++ - + - ΙΙ Ι 35.5 34.5 + - + + + - 
Right ++ - + - ΙΙ - 38 37 + - + + - - 28 1105 Sivam 68/M IP 
Left ++ + + - ΙΙ Ι 38.5 37.5 + - + + - - 
Right ++ ++ ++ + ΙΙ ΙΙ 38 38 + + + + + + 29 1161 Jalaluddin 66/M IP 
Left ++ + ++ + ΙΙ Ι 37.5 37 + + - + + - 
Right ++ + + - ΙΙ Ι 35 34.5 + - + + + - 30 1167 Mahendran 36/M IP 
Left ++ - + - ΙΙ - 34 34 + - + + + - 
 
LAB INVESTICATION – BEFORE TREATMENT REPORT – AZHAL KEEL VAYU 
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   PC EC 
1. AG3925 Violet 41/F 11.6 9050 60 34 1 5 10 22 - 123 24 0.7 194 3.6 -ve Nil Nil - - 
2. AG3985 Narayanan 53/M 14.5 9000 65 30 - 5 4 9 - 111 16 0.8 168 4.3 -ve Nil Nil 1-2 3-4 
3. AG4085 Subbulakshmi 52/F 10.2 9900 54 43 1 2 15 32 - 64 24 1.8 148 3.4 -ve Nil Nil 6-8 1-2 
4. AG4206 Jaya 45/F 13 9800 54 43 - 3 20 40 80 - 15 0.8 200 4.0 -ve Nil Nil 4-6 4-6 
5. AG4320 Rajamani 52/F 11.4 9400 62 33 - 5 10 22 - 128 14 0.8 193 3.7 -ve Nil Nil 4-6 4-6 
6. AG4326 Gnaneswari 38/F 12.1 9500 50 44 2 4 8 16 69 - 31 0.8 200 3.9 -ve Nil Nil - - 
7. AG4375 Padma 58/F 12.1 9700 58 34 2 6 4 10 - 89 25 0.8 187 3.9 -ve Nil Nil - - 
8. AG4378 Jayaraman 62/M 13.1 9600 55 40 - 5 6 15 78 92 19 0.8 185 4.3 -ve Nil Nil 1-2 2-4 
9. AG4785 Malligeswari 53/F 13.1 8500 58 34 - 8 4 8 84 - 70 0.8 200 4.2 -ve Nil Nil 3-4 2-3 
10. AG4807 Gomathi 42/F 13.5 9500 70 28 - 2 3 7 - 77 16 0.8 222 4.5 -ve Nil Nil 2-4 2-4 
11. AG4892 Mala 38/F 13 9800 55 42 - 3 14 28 - 76 28 0.8 200 4.5 -ve Nil Nil 2-4 2-4 
12 AG4916 Jegannathan 68/M 13.5 9800 59 36 - 5 17 40 73 88 13 0.8 169 4.8 -ve Nil Nil - - 
13 AG4943 Chandran 46/M 11.4 9800 52 46 - 2 10 12 - 85 17 0.8 213 3.7 -ve Nil Nil 2-4 2-4 
14. AG5035 Rukmani 50/F 13.5 9600 58 35 - 7 34 72 109 29 11 0.4 149 4.5 -ve Nil Nil 2.4 2.4 
15 AG5320 Ummakulzhan 36/F 13.1 8800 50 48 - 2 4 8 - 79 22 0.8 179 4.3 -ve Nil Nil 2.4 2.4 
16 AG6616 Lalitha 66/F 10.2 9500 55 41 - 4 10 22 - 63 18 0.6 166 3.4 -ve Nil Nil 2.3 2.3 
17 AG6634 Charlet 49/F 10.2 9700 55 41 - 4 10 22 - 63 18 0.6 166 3.1 -ve Nil Nil 2.3 2.3 
18 AG6993 Baby 59/F 10.7 9600 50 49 - 1 5 10 - 80 10 0.4 132 3.5 -ve Nil Nil 3.4 1.2 
19 AG7779 Anbu 51/M 13 9500 50 48 - 2 3 7 - 99 17 0.6 113 4.3 -ve Nil Nil 2.3 1.2 
20 AG7802 Ayyappan 58/M 8.3 9500 56 40 - 4 10 22 96 - 10 0.3 132 2.5 -ve Nil Nil 2.3 2.3 
21 AG7860 Pachaiyappan 54/M 13.1 9900 51 48 - 1 6 12 - 145 16 0.7 195 4.7 -ve Nil Nil 6.8 1.2 
22. 702 Rukmani 55/F 7.8 9800 52 44 1 3 12 25 77 - 10 0.5 142 2.4 -ve Nil Nil 2.3 1.2 
23. 722 Maniyammal 48/F 10.2 9500 55 43 - 2 5 10 79 - 19 0.8 152 3.4 -ve Nil Nil 2.4 1.2 
24 741 Ariyamala 69/F 10.6 8800 50 42 3 5 11 24 59 81 26 0.8 183 3.8 -ve Nil Nil 2.4 2.4 
25. 749 Vedhanayagam 51/F 13 9900 50 47 - 7 6 13 - 107 12 0.5 188 4.5 -ve Nil Nil 5.6 1.2 
26. 748 Mohana 64/F 12.1 9000 52 4 - - 2 4 - 101 26 0.6 194 3.9 -ve Nil Nil 4.6 4.6 
27 754 Andal 45/F 12.2 9600 50 47 - 3 6 12 66 - 18 0.5 158 4.5 -ve Nil Nil - - 
28 1105 Sivam 68/M 9.2 9000 54 44 - 2 5 11 - 24  0.8 175 3.0 -ve Nil Nil - - 
29 1161 Jalaluddin 66/M 16 9800 54 40 - 6 4 8 - 128 23 0.8 170 5.0 -ve Nil Nil - - 
30 1167 Mahendran 36/M 10.2 9800 51 43 2 4 6 14 - 106 26 0.8 170 3.2 -ve Nil Nil 2.4 2.4 
LAB INVESTICATION – AFTER TREATMENT REPORT – AZHAL KEEL VAYU 
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1. AG3925 Violet 41/F 11.6 9600 50 43 2 5 10 22 - 123 24 0.7 194 3.6 -ve Nil Nil - - 
2. AG3985 Narayanan 53/M 14.5 8300 50 45 - 5 4 9 - 111 16 0.8 168 4.3 -ve Nil Nil 1-2 3-4 
3. AG4085 Subbulakshmi 52/F 10.2 9000 54 40 1 5 15 32 - 64 24 1.8 148 3.4 -ve Nil Nil 6-8 1-2 
4. AG4206 Jaya 45/F 13 8000 54 41 2 3 20 40 80 - 15 0.8 200 4.0 -ve Nil Nil 4-6 4-6 
5. AG4320 Rajamani 52/F 11.4 7300 50 42 3 5 10 22 - 128 14 0.8 193 3.7 -ve Nil Nil 4-6 4-6 
6. AG4326 Gnaneswari 38/F 12.1 6700 50 44 2 4 8 16 69 - 31 0.8 200 3.9 -ve Nil Nil - - 
7. AG4375 Padma 58/F 12.1 7200 50 44 0 4 4 10 - 89 25 0.8 187 3.9 -ve Nil Nil - - 
8. AG4378 Jayaraman 62/M 13.1 6000 50 48 - 2 6 15 78 92 19 0.8 185 4.3 -ve Nil Nil 1-2 2-4 
9. AG4785 Malligeswari 53/F 13.1 7000 51 47 - 2 4 8 84 - 70 0.8 200 4.2 -ve Nil Nil 3-4 2-3 
10. AG4807 Gomathi 42/F 13.5 6700 51 47 - 02 3 7 - 77 16 0.8 222 4.5 -ve Nil Nil 2-4 2-4 
11. AG4892 Mala 38/F 13 9800 50 45 - 5 14 28 - 76 28 0.8 200 4.5 -ve Nil Nil 2-4 2-4 
12 AG4916 Jegannathan 68/M 13.5 9200 59 36 - 5 17 40 73 88 13 0.8 169 4.8 -ve Nil Nil - - 
13 AG4943 Chandran 46/M 11.4 6000 52 46 - 2 10 12 - 85 17 0.8 213 3.7 -ve Nil Nil 2-4 2-4 
14. AG5035 Rukmani 50/F 13.5 9600 58 35 - 7 34 72 109 29 11 0.4 149 4.5 -ve Nil Nil 2.4 2.4 
15 AG5320 Ummakulzhan 36/F 13.1 7000 50 48 - 2 4 8 - 79 22 0.8 179 4.3 -ve Nil Nil 2.4 2.4 
16 AG6616 Lalitha 66/F 10.2 7200 55 41 - 04 10 22 - 63 18 0.6 166 3.4 -ve Nil Nil 2.3 2.3 
17 AG6634 Charlet 49/F 10.2 7200 55 41 - 4 10 22 - 63 18 0.6 166 3.1 -ve Nil Nil 2.3 2.3 
18 AG6993 Baby 59/F 10.7 6200 50 49 - 1 5 10 - 80 10 0.4 132 3.5 -ve Nil Nil 3.4 1.2 
19 AG7779 Anbu 51/M 13 7600 50 48 - 2 3 7 - 99 17 0.6 113 4.3 -ve Nil Nil 2.3 1.2 
20 AG7802 Ayyappan 58/M 8.3 7800 56 40 - 4 10 22 96 - 10 0.3 132 2.5 -ve Nil Nil 2.3 2.3 
21 AG7860 Pachaiyappan 54/M 13.1 7200 51 48 - 1 6 12 - 145 16 0.7 195 4.7 -ve Nil Nil 6.8 1.2 
22. 702 Rukmani 55/F 7.8 7400 52 44 1 3 12 25 77 - 10 0.5 142 2.4 -ve Nil Nil 2.3 1.2 
23. 722 Maniyammal 48/F 10.2 6300 55 43 - 2 5 10 79 - 19 0.8 152 3.4 -ve Nil Nil 2.4 1.2 
24 741 Ariyamala 69/F 10.6 7400 50 42 3 5 11 24 59 81 26 0.8 183 3.8 -ve Nil Nil 2.4 2.4 
25. 749 Vedhanayagam 51/F 13 6700 50 47 - 7 6 13 - 107 12 0.5 188 4.5 -ve Nil Nil 5.6 1.2 
26. 748 Mohana 64/F 12.1 6800 52 4 - - 2 4 - 101 26 0.6 194 3.9 -ve Nil Nil 4.6 4.6 
27 754 Andal 45/F 12.2 6300 50 47 - 3 6 12 66 - 18 0.5 158 4.5 -ve Nil Nil - - 
28 1105 Sivam 68/M 9.2 5500 54 44 - 2 5 11 - 24  0.8 175 3.0 -ve Nil Nil - - 
29 1161 Jalaluddin 66/M 16 9000 54 40 - 6 4 8 - 128 23 0.8 170 5.0 -ve Nil Nil - - 
30 1167 Mahendran 36/M 10.2 7000 51 43 2 4 6 14 - 106 26 0.8 170 3.2 -ve Nil Nil 2.4 2.4 
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DISCUSSION 
 
 The drug Shanmuga Mezhugu was selected to find its efficacy in the treatment of 
Azhal Keel Vayu. 
 
 The therapeutic efficacy of Shanmuga Mezhugu in the disease of Azhal Keel Vayu 
is related to exploring pharmacological action like anti-inflammatory, analgesic, 
antipyretic and antiarthritic activity through clinical trials. 
 
 From various literatures, information which strongly supports the anti-
inflammatory, analgesic and antipyretic activity of the drug, the author has come to an 
idea about Shanmuga Mezhugu and its efficacy in Azhal Keel Vayu. 
 
 Biochemical analysis of the drug Shanmuga Mezhugu reveals the presence of 
minerals namely Calcium, Copper, Magnesium, Manganese, Mercury, Zinc and Iron. 
 
Calcium: 
 
 Calcium is the chief constituent of bones and teeth. It is required for the formation 
and physical strength of skeletal tissue. Calcium triggers muscle contraction and it is 
necessary for the transmission of nerve impulses. 
 
Copper: 
 
 Copper is necessary for the formation of red blood cells and other components of 
the blood system, and for healthy growth, development and maintenance of bone, 
connective tissue, brain, heart and many other body organs. Copper is also essential for 
the body’s manufacture of connective tissue. 
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 Copper like zinc and manganese, is used to form anti-inflammatory compounds in 
the body known as superoxide dismutase. Copper is a potent precursor of superoxide 
dismutase (SOD). This enzyme counteracts the joint inflammation that occurs with 
rheumatoid arthritis. Copper deficiency can result in increased lipid peroxidation, 
anaemia, bone and joint abnormalities like ruptured vertebral discs problems. 
 Copper has a mild anti-inflammatory effect. The use of copper bracelets in the 
treatment of arthritis has a long history, and wearers continue to claim positive results. 
 
Magnesium: 
 Magnesium contributes to the physical structure of the bone, being part of the 
bone’s crystal lattice, its “scaffolding”, along with calcium and phosphorous. The other 
portion of magnesium is found on the bone surface and acts as a storage site for 
magnesium that the body can draw upon during times of inadequate magnesium intake. 
Magnesium is necessary for calcium’s proper incorporation into bone by preventing a 
buildup of calcium into the soft tissues and joints. Magnesium is important as calcium in 
preventing osteoporosis. Oral supplementation with as much magnesium as calcium helps 
to prevent bone loss and increase the re-mineralization of weight-bearing, trabecular bone 
in post menopausal osteoporotic women. 
 
Manganese: 
 Manganese is predominantly stored in bones, liver, kidney and pancreas. It aids in 
calcium absorption and the formation of connective tissue, bones and blood clotting 
factors. 
 
 Manganese is a component of the antioxidant enzyme manganese superoxide 
dismutase (MnSOD). Antioxidants scavenge damaging particles in the body known as 
free radicals. These particles occur naturally in the body but can damage cell membranes, 
interact with genetic material and possibly contribute to the aging process as well as the 
development of a number of health conditions. Antioxidants such as MnSOD can 
neutralize free radicals and may reduce or even help prevent some of the damage they 
cause. 
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 Manganese functions in the antioxidant enzyme superoxide dismutase (MnSOD), 
which is deficient in patients with rheumatoid arthritis. Manganese supplementation has 
been shown to increase SOD activity, indicating increasing antioxidant activity. 
 
Zinc: 
 
 Zinc is found in high concentrations in red and white blood cells and is a 
constituent of the enzyme carbonic anhydrase. It is also found in the retina of the eye, 
bone, liver, kidney, pancreas and muscle tissue. Zinc plays an important role in the 
deposition of calcium salts in teeth and bones. 
 
 Zinc may have secondary antioxidant activity may protect membranes against 
oxidative damage. Zinc also comprises the structure of copper/zinc-superoxide dismutase 
(Cu/Zn-SOD). Zinc plays a structural role in Cu/Zn-SOD. Zinc may also have antioxidant 
activity via its association with the copper-binding protein metallothionein. 
 
 Zinc plays an important role in inflammation. Zinc levels are typically reduced in 
inflammatory conditions such as rheumatoid arthritis. Hence supplementation of zinc in 
rheumatoid arthritis patients may be ideal. 
 
Iron: 
 
 Iron plays a vital role in the transport of Oxygen to tissues and participation in 
cellular oxidation mechanism. Anaemia is one of the complications of rheumatoid 
arthritis. Iron supplements may support the patients with rheumatoid arthritis. 
 
Pharmacological studies: 
 
 In the acute toxicity studies no mortality is occurred up to the dose level of 
4000mg/kg. It proves that the above drug is having wide safety margin.  
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Anti-inflammatory activity: 
 Oral administration of Shanmuga Mezhugu have significant anti-inflammatory 
effect against formalin induced paw oedema in rats at the dose of 400 mg/kg body 
weight. 
 
Analgesic activity: 
 The drug Shanmuga Mezhugu was found to possess significant analgesic activity 
by Eddy’s hot plate method and acetic acid induced writhing in mice at the dose of 400 
mg/kg body weight. 
 
Antipyretic activity 
 The drug Shanmuga Mezhugu showed significant antipyretic activity in yeast 
induced hyper pyrexia in the rats. 
 
Clinical assessment: 
 For the clinical study of Shanmuga Mezhugu in ‘Azhal Keel Vayu’ 30 patients 
were selected. In these patients 80% of the patients showed good response to the 
treatment and 10% of the patients showed fair response. 
 
Siddha aspect: 
 The drug Shanmuga Mezhugu mentioned in Anupoga Vaithya Navaneetham for 
Keel Vayu. Major ingredient of the drug is Veeram. It has uppu and karppu suvaigal and 
has veppa veeriyam. 
  “வாத ேமலி	டா மர ள 
   ேசதற ெச சிைறய Ð ஓதேக 
   கார  வ!கச கா	"# $ைவெயலா 
   சார ப&கார# சா'(”. 16 
 
 Inippu, pulippu and uppu suvaigal normalize the vali kutram. 
 Veppa veeriyam also normalizes the vali kutram. 
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SUMMARY AND CONCLUSION 
 
 The drug Shanmuga mezhugu has been selected for the study to establish its 
efficacy in the management of Azhal Keel Vayu as an important aspect of this dissertation 
work. 
 
 The review of siddha literature about the drug describes the Anti-inflammatory, 
Antipyretic and analgesic activity of the drug. Information about the drug from various 
literatures was also referred. 
 
 Bio-chemical analysis of the drug reveals the presence of minerals namely 
calcium, copper, zinc, iron, manganese, mercury, magnesium and reducing sugar. 
 
 The acute toxicity study shows that the drug is safe and no significant adverse 
effects up to dose level of 4000mg/kg. 
 
 Pharmacological studies showed that the drug has got significant analgesic, anti-
inflammatory and antipyretic properties at the dose of 400 mg/kg and no significant 
adverse effects. 
 
 From the clinical assessment, it is inferred that the drug has marked response in 
Azhal Keel Vayu without any significant adverse effects. 
 
 This is concluded that the drug Shanmuga mezhugu has got significant Analgesic, 
anti-inflammatory and antipyretic activity, effective in Azhal Keel Vayu without causing 
any adverse effects. 
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 1 
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AN OPEN CLINICAL TRIAL OF SIDDHA DRUG KOVAI KIZHANGU 
CHOORNAM FOR THE TREATMENT 
OF NEERIZHIVU (DIABETES MELLITUS)  
- A PILOT STUDY 
BY 
 
Dr. K.RAJA, PG STUDENT, DEPT. OF GUNAPADAM 
 
FORM-I   SELECTION PROFORMA 
 
 
1. O.P.No / I.P No:  ________ 2.  Bed No: ________ 3. S.No: ________    
 
4. Name: ________________ 5. Age (years):        6. Gender: Male/Female  
 
7. Occupation: ____________________  8. Income: ____________________ 
 
9. Nationality: _____________________       10. Religion: ____________________ 
 
11. Address:  
  
 
                                                              
12. Complaints and duration:  
 
 
 
13. History of present illness:  
 
 
  
14. Past history:  
 
 
 
15. Menstrual history:  
 
 
    
16.  Social status: 
 
 1)  Low                        2) Middle                           3) High 
 
 
 2 
 
 
HABITS 
 
17. Smoker                                      
 
18. Alcoholic                   
 
19. Betal Nut chewer              
 
20. Non-vegetarian: 
 
GENERAL EXAMINATION 
 
21. Weight (kg):                                                    
        
22. Temperature (°F):        . 
  
23. Pulse rate / minute:                                          
 
24. Heart rate / minute:        
 
25. Respiratory rate / minute:                              
   
26. Blood pressure (mmHg):                               /       / 
 
27. Built:               Normosthenic                   Hypersthenic                      Hyposthenic 
                            
28. Nutrition:        Normal                              Overweight                        Underweight 
 
                                                      1. Yes                   2. No 
29. Pallor:                                 
 
30. Jaundice:                       
 
31. Cyanosis:  
           
32. Lymphadenopathy:  
  
33. Pedal oedema:  
  
34. Clubbing:                                
 
35. Jugular vein pulsation:            
 
36. Congenital Abnormalities     
 
37. Engorged Vein 
 
38. Abdominal Distension  
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    CLINICAL EXAMINATION 
 
   1. Yes                  2.No 
 
39. Polyuria   
 
40. Polydypsia 
 
41. Polyphagia 
   
42. Nocturia 
 
43. Tiredness 
 
44. Pain in the limbs 
 
45. Pain & burning sensation  
      in the both sole  
 
46. Paraesthesia in the feet 
   
47. Pruritus Vulvae 
 
48. Balanitis 
 
49. Asymptamatic 
 
 
EXAMINATION OF OTHER SYSTEMS 
 
                                               1. Normal         2. Affected 
 
50. CVS                                                                               __________________ 
       
51. RS                                                                                  __________________ 
 
52. CNS                                                  __________________ 
 
53. RENAL SYSTEM                     __________________ 
   
54. ENDOCRINE SYSTEM                                 __________________ 
 
55. NERVOUS SYSTEM                             __________________ 
 
 
  
 4 
 
 
 
 SIDDHA SYSTEM OF EXAMINATONS 
 
56. THINAI 
 
      1. Kurinji           2. Mullai                3. Marutham     
 
      4. Neithal                5. Palai 
      
 
 57. PARUVA  KAALAM 
 
 
     1. Elavenil kalam         2.Muthuvenil kalam 
  
     3. Mazhai kalam             4. Kulir kalam  
  
   5. Munpani kalam             6. Pinpani kalam     
 
58. YAKKAI 
  1. Vali                   2. Azhal           3. Iyam     
  
    4. Valiazhal       5. Valiiyam           6. Azhalvali   
    
  7. Azhaliyam     8. Iyavali            9. Iyaazhal  
  
59. GUNAM 
 
    1. Sathuva gunam                  2. Rajo gunam         
 
    3. Tamo gunam 
 
IYMPORIKAL  
                                      1. Normal        2. Affected 
  
60. Mei             _____________________ 
 
61. Vaai                    ______________________ 
 
62. Kan              _____________________ 
 
63. Mookku                        _____________________ 
 
64. Sevi                              _____________________ 
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 KANMENTHIRIUM  
                                       1. Normal       2. Affected 
 
65. Kai               _____________________ 
 
66. Kaal               _____________________ 
 
67. Vaai               _____________________ 
 
68. Eruvai           _____________________ 
 
69. Karuvaai          _____________________ 
                                                                                                                         
UYIR THATHUKKAL 
VALI 
                                        1. Normal       2. Affected 
 
70. Pranan                                         ____________________ 
 
71. Abanan                                         _____________________ 
  
72. Samanan                                          _____________________ 
 
73. Udhanan                                         _____________________ 
 
74. Viyanan                                         _____________________ 
 
75. Nagan                                         _____________________ 
 
76. Koorman                                          ______________________ 
 
77. Kirukaran                                        ______________________ 
 
78. Devathathan                                     ______________________ 
 
79. Tananjeyan            ______________________ 
   
    AZHAL 
                       1. Normal          2. Affected 
 
80. Anala pittham             _____________________ 
 
81. Prasaka pittham             _____________________ 
 
82. Ranjaka pittham                        ______________________ 
 
83. Aalosaka pittham                      ______________________ 
 
84. Saathaka pittham                  ______________________  
 6 
      
 
 IYAM 
                                          1. Normal          2. Affected                                     
 
85. Avalambagam          ______________________ 
 
86. Kilethagam                                                        ______________________  
 
87. Pothagam                        ______________________ 
 
88. Tharpagam                _______________________     
 
89. Santhigam                      ______________________ 
 
        
 UDAL THATHUKKAL 
                                     
      1. Normal         2. Affected 
90. Saaram                  _______________________ 
 
91. Chenneer                                                            _______________________ 
       
92. Oon                         _______________________ 
 
93. Kozhuppu                     _______________________ 
 
94. Enbu                        _______________________ 
     
95. Moolai                                       _______________________ 
 
96. Sukkilam / Suronitham         _______________________ 
         
  
ENVAGAI THERVUKAL 
 
                                        1. Normal        2. Affected 
97. Naa                                          _____________________ 
 
98. Niram                                      _____________________ 
 
99. Mozhi                               _____________________ 
 
100. Vizhi                               ______________________   
    
101.     Sparisam:  1.Mithaveppam         2.Miguveppam         
                    
        3. Thatpam 
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 Malam        1. Normal       2. Affected     
 
102. Niram                       
 
103. Nurai 
 
104. Karumai  
                                                  
105. Kalappu  
                     
106. Thanmai                      
    
 
Moothiram    
         
Neerkuri   
 
107. Niram                               ______________________ 
     
108. Eadai                                       ______________________ 
                                
109. Manam                             ______________________  
 
110. Nurai                             ______________________ 
 
111. Enjal                                      ______________________ 
  
 
112. Neikuri:       1.Vatham          2. Pittham         3. Khabam      
            
113. Naadi:    1.Vatham        2.Pittham                  3.khabam         
   
     4. Vathapittham             5. Vathakhabam            6. Pitthavatham   
  
     7. Pitthakhabam              8. Khabavatham            9. Khabapittham    
  
 
INVESTIGATION 
        
BLOOD 
 
114. TC (cells /cumm): 
 
DC (%):     115. P                116. L                117. E                118. B                  
 
119. M                       
 
120. Hb (gms %):                  . 
 
        ESR (mm/hr):        121. 1/2hr                     122.1hr 
 8 
 
 
123. Blood Sugar (F) (mg %): 
 
124. Post Prantial (mg %): 
 
125. Random (mg %) 
 
126. Blood Urea (mg %):     
 
127. Serum Creatinine (mg %):              .  . 
  
128. Serum Cholesterol (mg %): 
 
      URINE 
 
129. Albumin:      0. Nil  1. Trace  2. +  3. + + 
  
   4. + + +    
                                                                                                                                                                 
130. Sugar (F):     0. Nil  1. Trace  2. +   3. + +         
 
     4. + + + 
 
131. Sugar (PP):   0. Nil  1. Trace  2. +   3. + +         
 
      4. + + + 
         
Deposits                                1. Yes          2. No 
 
132. Pus cells                       
 
133. Epithelial cells            
 
134. RBC                               
 
135. Crystals                             
  
MOTION         
              Present (1)       Absent (2) 
136. Ova 
 
137. Cyst 
                                                                                                                                                                                                                                                        
138. Occult blood 
 
139. Pus cells   
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140. ADMITTED TO TRIAL:     1.Yes          2. No   
 
If yes   
 
141. S. No:    
                 
142. I.P / O.P       1. I.P        2. O.P  
 
143. Drug issued for OP patient (g): 
 
144. Station   
                                                                                                 146. Signature of the investigator 
145. Date:                                                                                      
 
        147. Signature of the doctor 
 
 1 
 
AN OPEN CLINICAL TRIAL OF SIDDHA DRUG KOVAI KIZHANGU 
CHOORNAM IN THE TREATMENT 
OF NEERIZHIVU (DIABETES MELLITUS)  
- A PILOT STUDY 
BY 
 
Dr. K.RAJA, PG STUDENT, DEPT. OF GUNAPADAM 
 
FORM-II ASSESSMENT PROFORMA 
 
1. O.P.No / I.P No:  ________ 2.  Bed No: ________ 3. S.No: ________    
 
4. Name: ________________  
 
5. Date of Admission to the trial  
 
6. Date of the Assessment  
 
7. Day of Assessment  
 
    CLINICAL ASSESSMENT    
 
   1. Yes                  2.No 
 
35. Polyuria   
 
36. Polydipsia 
 
37. Polyphagia 
   
38. Nocturia 
 
39. Tiredness 
 
40. Pain in the limbs 
 
41. Pain & burning sensation  
      in the sole 
42. Paraesthesia in the feet 
   
43. Pruritus Vulvae 
 
44. Balanitis 
 
45. Asymptomatic 
 2 
 
LAB INVESTIGATIONS (On Day 49)                                                                                           
 
BLOOD  
110. TC (cells /cumm): 
 
DC (%):     111. P                112. L                113. E                114. B                  
 
115. M                       
 
116. Hb (gms %):                  . 
 
        ESR (mm/hr):        117. 1/2hr                     118.1hr 
 
 
120. Blood Urea (mg %):     
 
121. Serum Creatinine (mg %):              .  . 
  
122. Serum Cholesterol (mg %): 
 URINE 
 
123. Albumin:      0. Nil  1. Trace  2. +  3. + + 
  
    4. + + +    
                                                                                                                                                            
Deposit                                1. Yes          2. No 
 
126. Pus cells                       
 
127. Epithelial cells            
 
128. RBC                               
 
129. Crystals                             
 MOTION         
                                          Present (1)        Absent (2)   
   
130. Ova 
131. Cyst                                                                                                                                                                                                                        
132. Occult blood  
133. Pus cells  
 
Date:                                                                                                Signature of the investigator 
 
Station:                Signature of the doctor 
  
 
A CLINICAL TRIAL OF SIDDHA DRUG KOVAI KIZHANGU CHOORNAM  
FOR THE TREATMENT OF NEERIZHIVU 
(DIABETES MELLITUS) 
- A PILOT STUDY 
 
CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 
 I certify that I have disclosed all details about the study in the terms readily 
understood by the patient. 
 
Date: _____________    Signature: _________________ 
 
Station: ___________     Name: ____________________ 
 
                                              
CONSENT BY PATIENT 
 
 I have been informed to my satisfaction, by the attending physician, the purpose 
of the clinical trial, and the nature of the drug treatment and follow-up including the 
laboratory investigations to be performed to monitor and safeguard my body functions. 
 
 I, exercising my free power of choice, hereby give my consent to be included as a 
subject in the clinical trial of Kovai Kizhangu Choornam on Neerizhivu. 
 
Date : ____________    Signature: __________________ 
  
Station : _____________    Name : ____________________ 
 
      Signature of witness: ________________ 
 
 
Date : ____________    Name: ______________________   
   
Station:  ___________    Relationship: _________________ 
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AN OPEN CLINICAL TRIAL OF SIDDHA DRUG SHANMUGA MEZHUGU FOR THE 
TREATMENT OF AZHAL KEEL VAYU 
(OSTEO ARTHRITIS) 
- A PILOT STUDY  
BY 
 
DR. K. RAJA, PG STUDENT, DEPT. OF GUNAPADAM 
 
FORM I- SELECTION PROFORMA 
 
1.  OP / IP NO.:___________   2.BED NO.:_________    3. S.NO:________________ 
 
4.  NAME: _______________ 5.  AGE (Yrs):                          6. GENDER:   M             F 
 
7.  DATE OF ADMISSION TO THE TRIAL  
 
8.  OCCUPATION: _________________   9. INCOME: _________________________ 
 
10. NATIONALITY: _________________ 11. RELIGION: _______________________ 
 
12. POSTAL ADDRESS: _________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
    
13.  COMPLAINTS & DURATION: __________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 
14. HISTORY OF PRESENT ILLNESS: ______________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 
15.  PAST HISTORY: ____________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 
16.  FAMILY HISTORY: __________________________________________________ 
 ________________________________________________________________ 
 
17.  SOCIAL STATUS: 
 
   1)  Low             2) Middle                          3) High 
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HABITS           Yes (1)            No (2) 
 
18.   Smoker 
 
19.   Alcoholic 
 
20.   Betalnut Chewer 
 
21.   Non – Vegetarian 
 
GENERAL EXAMINATION  
      
22.   Body Weight (kg)  
 
23.   Body Temperature (°F)         .        .   
 
24. Blood Pressure (mm/Hg)    
25 Pulse rate / min 
26. Heart Rate / min   
 
27. Respiratory rate / min 
 
28. Built 
                                   Normosthenic                   Hypersthenic                  Hyposthenic 
29. Nutrition 
                                   Normal                             Overweight                     Underweight 
 
        Yes (1)        No (2) 
 
30. Pallor 
31. Jaundice 
32. Clubbing 
33. Cyanosis 
 
34. Pedal oedema 
35. Lymphadenopathy 
 
36. Engorged veins 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
  
  
  
  
  
  
 
 
   
   
   
 3 
 
SYSTEMIC EXAMINATION 
 
A) INSPECTION 
 
37. Jointswelling:          1. Yes                                 2. No 
 
38. Muscle wasting:      1. Yes                                 2. No 
 
39. If Yes,                     1. Proximal                         2. Distal 
 
B) PALPATION                                             Present (1)     Absent (2) 
 
40. Local heat: 
 
41. Crepitation: 
 
42. Evidence of intra articular fluid: 
 
C) MOVEMENT                                               Yes (1)        No (2) 
 
43. Pain:    
 
44. Restriction:   
 
45. Swelling of the joint:         0. Nil                              1. Mild 
 
                                                 2. Moderate                    3. Severe 
 
46. Restriction of the joints:   0. Fully restriction                      1. Partially restriction 
 
                                               2. No restriction 
 
CLINICAL EXAMINATION                         Yes (1)       No (2) 
 
47. Arthritis of three or more joints: 
 
48. Morning stiffness: 
 
49. Heberden’s nodes:   
 
50. Bouchard’s nodes: 
 
EXAMINATIONS OF VITAL ORGANS 
                                                           Normal (1)            Abnormal (2) 
 
51. CVS                _____________________ 
 
52.  RS                   _____________________ 
 
53.  ABDOMEN       _____________________ 
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SIDDHA ASPECTS 
 
54.  NILAM 
 
       1.   Kurinji             2.  Mullai              3.  Marutham          4 .Neithal 5.Palai 
 
55. KALA IYALBU 
  
          1. Kaarkaalam                 2.  Koothirkallam           3.   Munpanikaalam      
 
          4. Pinpanikaalam              5.Ilavenirkaalam         6.Muduvenirkaalam 
 
56.  UDAL IYALBU 
 
1. Vatham                   2.Pitham                               3.Kabam      
 
4. Vatha Pitham       5. Vatha Kabam                   6.Pitha Kabam   
 
7. Pitha Vatham       8. Kaba Vatham                   9.Kaba Pitham 
 
57.  GUNA IYALBU 
 
 1. Sathuvam                  2.Rasatham                       3.Thamasam 
 
IYMPORIGAL                
                                     Normal (1)       Affected (2) 
  
58. Mei                                                   ___________________________________ 
 
59. Vaai                                                       ___________________________________ 
 
60. Kan                                                        ___________________________________ 
 
61. Mookku                                                 ___________________________________ 
 
62. Sevi                                                       ___________________________________ 
 
KANMENDHIRIUM / KANMAVIDAYAM 
                                      Normal (1)        Affected (2) 
 
63. Kai         ___________________________________ 
 
64. Kaal                                                        ___________________________________ 
 
65. Vaai                                                        ___________________________________ 
 
66. Eruvaai                                                   ___________________________________ 
 
67. Karuvaai                                                ___________________________________ 
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UYIR THATHUKKAL 
 
  VATHAM 
             Normal (1)    Affected (2) 
 
68. Pranan                                                   ____________________________________ 
 
69. Abanan                                                  ____________________________________ 
 
70. Viyanan                                         ___________________________________ 
 
71. Uthanan                                          ___________________________________ 
 
72. Samanan                                               ____________________________________ 
  
73. Nagan                                         ____________________________________ 
 
74. Koorman                                        ____________________________________ 
 
75. Kirukaran                                              ____________________________________ 
 
76. Devathathan                                       ____________________________________ 
 
77. Dhananjeyan                                         ____________________________________ 
 
PITHAM 
                    Normal (1)   Affected  (2) 
78. Anar pittham                                    ____________________________________ 
 
79. Ranjagam                                    ____________________________________ 
 
80. Sathagam                                            ____________________________________ 
  
81. Alosagam                                    ____________________________________ 
 
82. Prasagam                                            ____________________________________ 
 
KABAM 
                 Normal (1)    Affected  (2) 
 83. Avalambagam                                    _____________________________________ 
   
84. Kiletham                                    _____________________________________ 
 
85. Pothagam                                    ______________________________________ 
 
86.  Tharpagam                                    ______________________________________ 
 
87. Santhigam                                          ______________________________________ 
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UDAL THATHUKKAL 
                        Normal (1)   Affected (2) 
88. Saaram                                               _____________________________________ 
 
89. Senneer                               _____________________________________ 
 
90. Oon                                                _____________________________________ 
 
91. Kozhuppu                                    _____________________________________ 
 
92. Enbu                                                  _____________________________________ 
 
93. Moolai                                               _____________________________________ 
  
94. Sukkilam /                                         _____________________________________ 
  Suronitham 
 
 ENVAGAI THERVUGAL 
            Normal (1)   Affected (2) 
95. Naa                                                 ____________________________________ 
 
96. Niram                                                   ____________________________________ 
 
97. Mozhi                                             ____________________________________ 
 
98. Vizhi                                                   ____________________________________ 
 
99. Sparisam                                               ____________________________________ 
 
100. Naadi 
                  __________________________________________________________ 
 
MALAM 
                Normal (1)    Affected (2) 
101.    Niram     
                   
                                          Yes (1)     No (2) 
102.    Nurai        
 
103.    Erugal         
 
104.    Elagal 
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MOOTHIRAM 
Neerkuri  
       Normal (1)     Affected (2) 
105.  Niram   
 
106.  Manam         
 
107.  Edai        
 
108.  Nurai   
 
109.  Enjal      
   
110.  Neikuri 1.Vatha Neer  2.Pitha Neer  3. Kaba Neer 
 
 
LAB INVESTIGATIONS 
 
          BLOOD 
 
111. TC (Cells/Cumm) 
  
        DC (%):  112.N               113.L              114.M  
    
  115. E       116.B  
  
 ESR (mm)     117.½ Hr         118.1 Hr 
 
119. Hb (gm%)        .   
 
Blood Sugar (mg %) 
 
                   120. Fasting                       121. Post – prandial                    
 
122. CRP 
 
123. RA Factor 
 
124. ASO titre 
 
125. VDRL 
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                  URINE 
           Present (1) Absent (2)  
126. Albumin                                                               ______________________________ 
   
127. Sugar                                                                    ______________________________ 
 
128. Deposits 
 
129. ADMITTED TO TRIAL:   
                                                 1. YES                           2. NO    
 
130.  IF YES,  
                         S.NO         
 
131.  IP (1)                                OP (2) 
 
 
DRUGS ISSUED FOR PATIENTS 
 
132.  No. of capsules (of 130 mg each)      ________________   
 
 133.  Date: _______________    134. Signature of investigator: _____________ 
 
 135. Station: ______________   136. signature of doctor: ___________________ 
 
  
  
  
 1 
                                          
 
AN OPEN CLINICAL TRIAL OF SHANMUGA MEZHUGU   FOR THE 
TREATMENT OF AZHAL KEEL VAYU 
- A PILOT STUDY 
 
FORM II-ASSESSMENT PERFORMA 
 
1. OP/IP No:_________________              2.BED No:_______3.S.No:_______________ 
 
4. NAME:__________________________ 
 
5. DATE OF ADMISSION: 
 
6. DATE OF ASSESSMENT: 
 
7. DAY OF ASSESSMENT: 
 
CLINICAL EXAMINATION 
 
     SIGNS AND SYMPTOMS         
 
      Right   Left 
  
                              1. Yes       2. No     1. Yes       2. No 
   8. Pain 
        
9. Stiffness 
                                 
  10. Limitation of movement 
                                                
11. Tenderness 
                                                                            
12.  Crepitation on movement 
        
      13. Swelling 
  
14. Measurement (in cm) 
 2 
 
 
 
  ENVAGAI THERVUKAL 
                                    1. Normal        2. Affected 
16. Naa                                          _____________________ 
 
17. Niram                                      _____________________ 
 
18. Mozhi                               _____________________ 
 
19. Vizhi                                                            ______________________   
          
Malam        1. Normal       2. Affected     
 
20. Niram                  ______________________ 
 
21. Thanmai                  ______________________ 
    
Moothiram    
         
Neerkuri   
 
22. Niram                         ______________________ 
 
23. Eadai                                              _____________________ 
                                
24. Manam                            ______________________  
 
25. Nurai                         ______________________ 
 
26. Enjal                               ______________________ 
 
 
Neikuri:  27.Vali                            28. Azhal                       29. Iyam      
 
 
Naadi:    30. Vali                    31. Azhal                 32. Iyam         
   
     33. Valiazhal                 34. Valiiyam                 35. Azhalvali   
 
  
     36. Azhaliyam               37. Iyavali                     38. Iyaazhal    
    
Sparisam:       39. Mithaveppam         40. Miguveppam         
                    
 41. Thatpam 
 
 3 
 
INVESTIGATION (ONLY ON DAY 49) 
 
BLOOD 
 
42. TC (cells /cumm): 
 
43. DC (%):    1. P                   2. L                    3. E                      4. B                  
 
  5. M                       
 
44. Hb (gms %):                  . 
 
45. ESR (mm/hr):        1. 1/2hr                           2.1hr 
 
46. Blood Sugar (R) (mg %): 
 
47. Blood Urea (mg %): 
 
48. Serum Creatinine (mg %):              .  . 
  
49. Serum Cholesterol (mg %): 
 
 
 
 
URINE 
 
50. Albumin:      0. Nil  1. Trace  2. +  3. + + 
  
    4. + + +    
                                                                                                                                                                 
51. Sugar:            0. Nil  1. Trace  2. +   3. + +         
 
      4. + + + 
 
 
52. Deposit                           1. Yes          2. No 
 
1. Pus cells                       
 
2. Epithelial cells             
 
3. RBC                               
 
4. Crystals                             
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53. X – Ray Knee: _______________________________________________________ 
 
54. RESULT:            Cured                         Improved                       No change 
 
FOR O.P.PATIENTS: 
 
55. Drugs returned: 
    1. No. of capsules (of 130 mg each): ___________ 
 
 
 
56. Drugs issued 
               1. No. of capsules (of 130 mg each): ____________ 
 
 
Date:       
Signature of Investigator 
       
Station:                                     
Signature of Doctor 
 
 
  
 
A CLINICAL TRIAL OF SIDDHA DRUG SHANMUGA MEZHUGU  
FOR THE TREATMENT OF AZHAL KEEL VAYU 
(OSTEOARTHRITIS) 
- A PILOT STUDY 
 
CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 
 I certify that I have disclosed all details about the study in the terms readily 
understood by the patient. 
 
Date: _____________    Signature: _________________ 
 
Station: ___________     Name: ____________________ 
 
                                              
CONSENT BY PATIENT 
 
 I have been informed to my satisfaction, by the attending physician, the purpose 
of the clinical trial, and the nature of the drug treatment and follow-up including the 
laboratory investigations to be performed to monitor and safeguard my body functions. 
 
 I, exercising my free power of choice, hereby give my consent to be included as a 
subject in the clinical trial of Shanmuga mezhugu on Azhal Keel Vayu. 
 
Date : ____________    Signature: __________________ 
  
Station : _____________    Name : ____________________ 
 
      Signature of witness: ________________ 
 
 
Date : ____________    Name: ______________________   
   
Station:  ___________    Relationship: _________________ 
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